

UC San Diego

UC San Diego Previously Published Works

Title

Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics

Permalink

<https://escholarship.org/uc/item/4z04x122>

Authors

Zhang, Jing
Hu, Zhimin
Horta, Calista A
[et al.](#)

Publication Date

2023

DOI

10.1016/j.semcancer.2022.12.002

Peer reviewed



Published in final edited form as:

Semin Cancer Biol. 2023 January ; 88: 46–66. doi:10.1016/j.semcancer.2022.12.002.

Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics

Jing Zhang^{a,1}, Zhimin Hu^{a,1}, Calista A. Horta^a, Jing Yang^{a,b,*}

^aDepartment of Pharmacology, Moores Cancer Center, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA

^bDepartment of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093, USA

Abstract

Epithelial–mesenchymal transition (EMT) has been implicated in various aspects of tumor development, including tumor invasion and metastasis, cancer stemness, and therapy resistance. Diverse stroma cell types along with biochemical and biophysical factors in the tumor microenvironment impinge on the EMT program to impact tumor progression. Here we provide an in-depth review of various tumor microenvironmental signals that regulate EMT in cancer. We discuss the molecular mechanisms underlying the role of EMT in therapy resistance and highlight new therapeutic approaches targeting the tumor microenvironment to impact EMT and tumor progression.

Keywords

Epithelial-Mesenchymal Transition (EMT); Invasion and metastasis; Extracellular matrix (ECM); Hypoxia; Tumor stroma

1. Introduction

During tumor development, the dynamic interactions between tumor cells and their cellular and extracellular tissue microenvironment foster malignant progression and metastasis. Epithelial–mesenchymal transition (EMT) is a cellular process in which cells lose their epithelial characteristics (E-cadherin) and acquire mesenchymal features (N-cadherin, vimentin). EMT has been shown to promote the tumor initiation ability, linking EMT to cancer stem cells (CSCs) as well as playing integral roles in tumor invasion and metastasis [1–3].

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Correspondence to: UCSD Moores Cancer Center, 3855 Health Sciences Drive, MC0819, La Jolla, CA 92093-0819, USA.

jingyang@ucsd.edu (J. Yang).

¹The first two authors contributed equally to this work.

Conflicts of interest

The authors declare no conflict of interest.

Studies in mouse tumor models and human circulating tumor cells show that EMT is not a binary process during metastasis. In human breast cancer patients, circulating tumor cells (CTCs) present diverse EMT statuses and many CTCs express both epithelial and mesenchymal markers [4]. The intermediate EMT cells, named as hybrid-EMT or partial-EMT, exhibit both mesenchymal and epithelial properties. More recent studies described multiple intermediate EMT states in mouse and human tumor samples by single cell RNA-seq [5–8]. Tumor cells in various partial-EMT states contribute to tumor heterogeneity and cancer stem cell properties [9]. Using a skin tumor model, Tsai et al. show that induction of EMT promotes skin tumor invasion and dissemination; while reversion of EMT is essential for the regrowth of distant metastases [10]. Several in vivo lineage tracing studies have been performed in mouse breast tumor models to determine the role of EMT plasticity in tumor metastasis. Fisher et al. initially performed Fsp1 (fibroblast specific protein 1) and Vimentin promoter-driven Cre-mediated lineage tracing in the MMTV-PyMT breast tumor model and did not observe a requirement of EMT in generating lung metastasis [11]. Later, Li et al. used an elegant dual lineage-tracing system to demonstrate that transient activation of N-cadherin, which marks a partial EMT state, but not activation of vimentin, is required for tumor metastasis in the MMTV-PyMT breast tumor mouse model [12]. EMT marker specificity and lineage tracer sensitivity might contribute to this discrepancy. Bornes et al. reported that Fsp1, the same mesenchymal marker used in Fischer et al. study, was unable to trace most of the mesenchymal cells during tumor metastasis in the PyMT mouse model [13]. More recently, Luond et al. showed that partial EMT, not full EMT, contributes to lung metastasis in the MMTV-PyMT breast cancer mouse model. However, full EMT exhibited higher resistance to chemotherapy and facilitated tumor survival under stress [14]. Activation of partial EMT promoted collective migration and led to higher cell plasticity and metastasis capacity; in contrast, full EMT was difficult to reverse at distant organs, leading to reduced metastasis [14,15]. Therefore, epithelial-mesenchymal plasticity plays a critical role in tumor progression, metastasis, and therapy resistance [9].

The EMT program is orchestrated by a core group of EMT-inducing transcription factors (EMT-TFs), including the SNAIL family SNAIL [16, 17] and SNAIL2 [18], the ZEB family ZEB1 [19] and ZEB2 [20], and the TWIST family TWIST1/2 [21–23]. The SNAIL and ZEB family transcription factors directly repress E-cadherin expression by binding E-boxes at its promoter region, thereby leading to EMT. TWIST1 induces invadopodia-mediated matrix degradation to facilitate tumor invasion and metastasis [21,24]. EMT-TFs recruit epigenetic regulators to regulate their target genes expression. For example, SNAIL recruits HDAC1 and EZH2 to repress E-cadherin expression. ZEB1 recruits HDAC1 or DNMT1 to repress target gene expression [25]. Of note, the EMT-TFs regulate the transcription of each other and cooperate to orchestrate EMT progression [5,26]. For example, TWIST1 binds to the SNAIL2 promoter and induces its transcription [27]. Many EMT-TFs are regulated by miRNAs. miR-200 family members and miR-205 repress ZEB1/2 expression to reverse EMT and suppress migration and invasion in various cancer types [28–30]. Reciprocally, ZEB1 was shown to directly repress the miR-200 family members to promote EMT and stemness acquisition, suggesting a negative feedback loop between miR-200 and ZEB [31,32]. Similarly, the EMT/MET switch could also be toggled by SNAIL/miR-34 circuit regulation [33].

The EMT/MET switches are controlled by both biochemical and biophysical factors in the tumor microenvironment to impact tumor development, progression, and treatment responses. The tumor microenvironment is largely composed of immune cells, stromal cells, blood vessels, and extracellular matrix, though the relative proportion of these components may vary in individual tumors. This review explores these environmental factors regulating EMT to reveal potential therapeutic targets and to predict treatment responses.

2. Regulation of EMT by the tumor microenvironment

2.1. Extracellular matrix in EMT regulation

Extracellular matrix (ECM) is a critical component of the tumor microenvironment that contributes to tumorigenesis and progression. Many ECM proteins, such as collagen I, hyaluronic acid (HA) and fibronectin, have been implicated in promoting EMT. Increasing ECM protein deposition and remodeling drive malignant progression partly via EMT. In addition to direct binding of ECM proteins to tumor cells to activate the downstream biochemical signaling, matrix stiffening during tumor progression exerts increased mechanical forces on tumor cells, which induces EMT and increases the risk of cancer development and progression.

2.1.1. ECM molecules in EMT regulation—The extracellular matrix molecules, including collagens, fibronectin and hyaluronan, all contribute to EMT activation (Fig. 1). Type IV collagen, a major component of the basement membranes, is essential for the maintenance of the epithelial properties of epithelial cells. Disruption of collagen IV deposition could upregulate TGF β , a major inducer of EMT [34–36]. Collagen I induces EMT in lung cancer cells by activating PI3K/ERK signaling, which in turn stimulates the autocrine secretion of TGF- β 3 to induce EMT[37]. Collagen I also binds to the collagen I receptor DDR2 to promote SNAIL nuclear accumulation and increases SNAIL protein level by inhibiting SNAIL ubiquitylation. In turn, SNAIL further upregulates Membrane type I-matrix metalloproteinase (MT1-MMP) and collagen I to sustain the EMT phenotype and facilitate tumor cell invasion [38]. Fibronectin is a marker of cells that have undergone EMT. During EMT, fibronectin assembly is increased, and fibronectin fibril formation is induced by TGF- β 1. Fibronectin fibrils serve as an integration point for mechanical signals and TGF- β 1 signaling to induce EMT. High levels of fibronectin have been detected in the stroma of breast tumors [39]. Fibronectin activates FAK and leads to recruitment of Src through binding to integrins. Cooperation between fibronectin and TGF β is required to activate Src and ERK/MAPK to induce EMT[40]. HA is another important ECM molecule that is overproduced in many types of human tumors. HA is a key ligand of CD44, a cell surface glycoprotein that plays a critical role in cell migration, invasion, and cancer stem cell properties. The binding of HA to CD44 elicits high-affinity interaction between CD44 and the TGF β receptor I, which increases downstream SMAD2/SMAD3 activation to induce EMT[41]. HA/CD44 interaction was also reported to cause CD44 to translocate into the nucleus and promote de novo transcription of lysyl oxidase (LOX), leading to TWIST1-dependent induction of EMT[42]. Taken together, ECM proteins, when dysregulated in cancer, directly affect EMT.

2.1.2. ECM remodeling in EMT regulation—Growing evidence suggests that increased ECM remodeling and deposition also drive malignant progression (Fig. 1). Matrix metalloproteinases (MMPs)-mediated ECM protein remodeling and LOX-mediated ECM protein crosslinking both play crucial roles in the EMT process. MMPs in the tumor environments are reported to participate in EMT induction. MMP-2 was found to degrade a wide variety of ECM proteins including fibronectin, collagen IV and collagen V [43–45]. High expression of MMP-3, a stromal enzyme upregulated in many breast tumors, induced expression of an alternatively spliced form of Rac1 and caused an increase in cellular reactive oxygen species. The reactive oxygen species could stimulate SNAIL expression to facilitate cancer progression[46]. Lysyl oxidase (LOX) is an extracellular copper-dependent enzyme that promotes crosslinking of collagens or elastin to increase ECM tensile strength[47,48]. LOXL2 and LOXL3 are two members of the LOX gene family which can interact with and stabilize SNAIL to downregulate E-cadherin expression, leading to an induction of EMT. Knockdown of LOXL2 in SNAIL-expressing metastatic carcinoma cells decreased tumor growth and reduced expression of mesenchymal markers and invasion, providing a direct link between LOXL2 and SNAIL in tumor progression[49]. LOX can also bind and transactivate the SNAIL2 promoter, and LOX/SNAIL2 axis mediates TIMP4 (TIMP: tissue inhibitors of matrix metalloproteinases that can regulate the proteolytic activity of MMPs) secretion, then facilitating EMT progression[50]. Hypoxia induced the expression of LOX and LOXL2 via HIF1, which then repress E-cadherin to induce EMT [51]. From these studies, it is evident that ECM reorganization directly regulates EMT to impact tumor progression.

2.1.3. ECM-exerted mechanical force in EMT regulation—Tumor cells and stromal cells also respond to ECM stiffening-induced mechanical signals during tumor progression. Matrix rigidities can be sensed and transmitted across the plasma membrane by various mechanosensors, several of which are implicated in EMT regulation. Integrins are the best studied mechanosensors and play a critical role in driving EMT and invasion[52–54]. Blockade of integrin signaling via integrin-blocking antibodies completely abolished stiffness-induced EMT in breast cancer cells [55]. Many α V integrins, especially α V β 6, α V β 3 and α V β 5, are expressed at low levels in healthy epithelial tissues, but are upregulated during EMT [56,57]. Disruption of β 1 integrin induced α V β 3 integrin switching and promoted TGF β activation in E-cadherin-positive triple-negative breast cancer (TNBC) cells via a TGF β -miR-200-ZEB signaling network to induce EMT and enhance dissemination[58]. DDR2 regulates the activation state of collagen-binding integrins α 1 β 1 and α 2 β 1, thus strengthening cell-ECM interactions and maintaining the mesenchymal phenotype in tumor cells [59,60]. ECM regulates MT1-MMP localization via β 1 or α V β 3- integrins [61]. Colocalization and cooperation between β 1-integrin and MT1-MMP1 plays an important role in EMT and early cancer dissemination by upregulating the Wnt signaling[62]. Integrin-linked kinase (ILK), as a mechanotransducer, is crucial for TGF- β 1-induced EMT via the TWIST1-integrin β 1-FAK/ILK pathway[63–65]. ECM stiffening is also reported to activate the mechanosensor Piezo1, which activates TGF β signaling by recruiting Rab5c, thus promoting EMT and tumor progression[66,67]. TRPV4, a mechano-sensitive ion channel regulating calcium influx, promoted EMT and cell migration in breast cancer cells [68,69].

Several EMT transcription factors are regulated by mechanical forces exerted by ECM in the tumor microenvironment (Fig. 1). Increasing matrix stiffness in the tumor stroma activates TWIST1, a key mechano-responder to drive EMT and invasion at matrix stiffness. Mechanistically, high matrix stiffness releases the TWIST1 protein from binding to its cytoplasmic anchor protein G3BP2. TWIST1 then translocates into the nucleus to drive the transcriptional program of EMT and tumor invasion[55,70,71]. Upstream of TWIST1, high matrix stiffness activates ERK/RSK and leads to ligand independent EPHA2 S897 phosphorylation. EPHA2 then binds to and activates Lyn to phosphorylate TWIST1 and prevents its association with G3BP2, thus leading to TWIST1 nuclear translocation to promote EMT and invasion[55,72]. SNAIL protein stability is regulated by matrix stiffness via DDR2. DDR2 activation led to activation of ERK, which directly phosphorylates SNAIL to promote SNAIL nuclear accumulation and reduces SNAIL protein ubiquitylation, thus facilitating tumor cells to undergo EMT and invade through collagen I-rich extracellular matrices [38]. In summary, critical ECM molecules and mechanical forces exerted by tumor ECM can impinge on EMT transcription factors to regulate EMT.

2.2. Stromal and immune cells in EMT regulation

In the tumor microenvironment, stromal and immune cells secrete various cytokines and chemokines, which act in a paracrine fashion on nearby carcinoma cells. Some of these paracrine signals, often acting in combination, are potent inducers of EMT in carcinoma cells to promote tumor progression and metastasis.

2.2.1. Cancer-associated fibroblasts—Cancer-associated fibroblasts (CAFs) are a major component of the tumor stroma and play a critical role in facilitating crosstalk between cancer cells and the tumor microenvironment. Numerous studies revealed that CAFs could secrete TGF β [73], HGF[74], FGF[75], SDF-1 [76], IL-6[77], IL-32[78], CCL5[79], CXCL12 [80], MMP-2[81], and MMP-9 [82] to enable the EMT process in various cancer cells[83,84] (Fig. 2). In breast cancer and bladder cancer cells, TGF β 1 secreted by CAFs activated the canonical SMAD-mediated and SMAD-independent pathways, both of which play important roles during EMT induction [73,85,86]. For the canonical SMAD pathway, activated SMAD3/4 upregulated the expression of EMT-TFs, including SNAIL1/2, TWIST1/2 and ZEB1/ZEB2 [87–89]. In the SMAD-independent non-canonical pathway, TGF β activates MAPK/ERK, PI3K/AKT and Rho GTPase to aid EMT initiation[34]. Additionally, IL-6 secreted by CAFs induced EMT via STAT3 in ovarian, bladder, gastric and hepatocellular carcinoma cancer cell lines [77,90–92]. Mesenchymal stem cell (MSC)-derived CAFs or radiation-activated CAFs were shown to secrete enhanced levels of CXCL12, which bound to CXCR4 in tumor cells and stimulated EMT and metastasis in pancreatic and prostate cancer cells respectively [93, 94]. Li et al. suggested the CXCL12/CXCR4 axis activated the p38 kinase pathway to facilitate CAFs-mediated EMT[94]. Moreover, activated CAFs secreted MMP-2 and MMP-9 to remodel ECM, thereby facilitating EMT in prostate cancer cells [82]. In hepatocellular carcinoma cells, CAFs secreted HGF to stimulate the c-MET/FRA1/HEY1 axis and contributed to tumor invasion and metastasis both in vitro and in vivo [74]. More recently, several studies reported the existence of different subtypes of CAFs with distinct functions in the TME [95,96]. In particular, Öhlund et al. demonstrated two subtypes of CAFs, myofibroblastic

CAFs (myCAFs) and inflammatory CAFs (iCAFs), in the PDAC microenvironment [95]. myCAFs exhibited high levels of α -SMA and were found in close proximity to tumor cells[95]. In contrast, iCAFs showed lower α -SMA levels but highly expressed IL-6 and were located farther from tumor regions[95]. Co-culture with iCAFs, but not myCAFs, significantly upregulated ZEB1 and Vimentin expression and induced partial EMT in colon tumor organoids[97]. Taken together, CAFs in the tumor microenvironment secrete various molecules to impact EMT and metastasis.

2.2.2. Cancer-associated adipocytes—Obesity, featuring the expansion of white adipose tissue, has been associated with malignant cancer progression. Adipose tissue consists of adipocytes, adipose mesenchymal stem/stromal cells (ASCs), endothelial cells, and immune cells [98]. Coculturing cancer cells with adipocytes or ASCs were shown to stimulate EMT in cancer cells by secreting IL-6 and activating IL-6/STAT3 pathway [99–101]. IL-6[100], Leptin [102–104], ETP[105], FABP4[106], TGF- β 1[107,108], CCL5[109,110] and CXCL12[111] secreted by ASCs or adipocytes were reported to promote EMT in various cancer cell lines(Fig. 2). Leptin binds to leptin receptor (OB-R) and contributes to the EMT process by activating multiple pathways, including PI3K/AKT which phosphorylates GSK3 β to increase β -catenin nuclear translocation, STAT3 which recruits G9a to regulate the miR-200c/ZEB1 feedback loop, and ERK which represses E-cadherin and increases vimentin expression[112–115]. FABP4 is shown to activate AKT/GSK3 β /SNAI1 pathway, thereby facilitating EMT in cervical squamous cell carcinoma (CSCC) cells[116]. In the PyMT breast tumor mouse model, ETP augments EMT and metastasis by activating the TGF- β signaling pathway[105].

2.2.3. T Lymphocytes—T lymphocytes, such as CD4⁺ T cells and CD8⁺ T cells, play an important role in immune responses to tumors [117]. Numerous studies show that CD4⁺ T cell or CD8⁺ T cell infiltration inhibited tumor growth and correlated with a better prognosis [118–122]. However, some reports suggest they also promote tumor metastasis by inducing EMT in certain cancer cell lines. In breast cancer, CD8⁺ T cells were reported to induce EMT and confer cancer cells with stemness characteristics, although the underlying mechanism is unclear[123]. In pancreatic ductal adenocarcinoma (PDAC) cells, Goebel et al. reported that CD4⁺ T-effector cells stimulated EMT by secreting TNF α and IL-6. Co-culture with T-effector cells significantly upregulated ZEB1 in tumor cells, suggesting that T-effector cells-induced EMT might depend on ZEB1 [124]. More recently, Salazar et al. showed that CD4⁺ Th9 and CD4⁺ Th17 cells secreted IL-9 or IL-17, respectively and enabled lung cancer cells to undergo EMT both in vitro and in vivo[125]. In a xenograft mice model of lung cancer, co-injection of tumor cells with Th9 or Th17 cells significantly increased EMT and metastasis, while Th9 and Th17 blocking antibodies inhibited EMT and tumor progression[125]. Regulatory T cells (Tregs) are a subset of CD4⁺ T cells mainly responsible for self-tolerance and homeostasis maintenance of T cells. Several studies revealed that Tregs could stimulate EMT in lung epithelial cells, hepatocellular carcinoma and melanoma cells [126–128]. In the Oh et al. study, melanoma cells co-injected with Tregs exhibited increased EMT and metastasis in vivo. TGF β secreted by Tregs contributed to EMT in hepatocellular carcinoma and melanoma cells[128](Fig. 2). Therefore, in addition to

their critical roles in tumor immunity, T lymphocytes could impact EMT in tumor cells via cytokine production.

2.2.4. Macrophages—Macrophages in the tumor microenvironment are known as tumor-associated macrophages (TAMs)[129,130]. TAMs infiltration correlated with higher EMT and poor clinical outcomes in various cancers, including breast cancer, hepatocellular carcinoma, gastric cancer, colorectal cancer and lung cancer [131–138]. Macrophages in tumors are often divided into M1 and M2 macrophages. M1 macrophages secrete numerous pro-inflammatory cytokines and are considered to be anti-tumorigenic. In contrast, M2 macrophages mainly produce anti-inflammatory cytokines and exhibit pro-tumorigenic properties. Yeung et al. reports that M2 macrophages predominantly promoted EMT and metastasis in an orthotopic liver tumor mouse model[135]. Additionally, high M2 macrophages infiltration is positively associated with tumor aggressiveness and poor prognosis in bladder cancer and clear cell renal cell carcinoma(ccRCC) patients [139,140]. TAMs secrete numerous cytokines or chemokines to induce EMT in cancer cells, including TGF β , TNF α , IL-6, IL-8, IL-10, G-SCF, CXCL13, CCL18, CCL22 and other factors [132–135,140,141–145](Fig. 2). In lung and colon carcinomas, macrophages could secrete TNF α , which synergizes with TGF β to stimulate EMT [142,146]. Similarly, M2 macrophages also induced EMT by releasing TGF β , resulting in β -catenin and SMAD2 activation in non-small cell lung cancer(NSCLC) cells and lung epithelial cells[141,147]. Additionally, IL-6 secreted by macrophages induced EMT by various mechanisms. In the Che et al. study, COX2 was upregulated by IL-6, which induced PEG2 and β -catenin nuclear translocation, thereby promoting EMT in lung cancer cells [148].

Reciprocally, tumor cells could secrete cytokines to recruit macrophages and induce M2 polarization of macrophages, reinforcing tumor progression and metastasis. Several studies uncovered the feedback loop between macrophages infiltration and tumor cells. In colon cancer cells, TAMs secreted IL-6 to stimulate EMT. Meanwhile, IL-6 activated the JAK2/STAT3/FoxA1 signaling in colon cancer cells, which led to high levels of CCL12 secretion in cancer cells to recruit more macrophages [149]. Similarly, Su et al. revealed that macrophages secreted CCL18 to activate NF- κ B, thus enabling breast cancer cells to undergo EMT [132].

2.2.5. Myeloid-derived suppressor cells (MDSCs)—MDSCs are a population of heterogeneous immature myeloid cells that accumulate in the tumor microenvironment and have been shown to facilitate tumor progression by repressing anti-tumor immune responses and promoting angiogenesis [150,151]. MDSCs are generally divided into two subsets, polymorphonuclear/granulocytic MDSCs (PMN-MDSCs/G-MDSCs), which account for 70%–80% of MDSCs, and monocytic MDSCs (MO-MDSCs) [150,151]. MDSCs are shown to stimulate EMT in various cancer cell types [152–156](Fig. 2). MDSCs stimulated EMT by secreting TGF β , VEGF, IL-6, IL-10 and IL-28 in melanoma, breast cancer and lung cancer [154,156–160]. Peng et al. reports that IL-6 and Nitric Oxide (NO) produced by MDSCs led to STAT3 and NOTCH activation, respectively, conveying stemness and EMT properties to breast cancer cells[157]. Li et al. reported that co-culture of nasopharyngeal carcinoma cells with MDSCs activated the COX2/ β -catenin/TCF4 pathway via TGF β

and NO secretion to provoke EMT[154]. In human NSCLC xenograft models, MDSCs stimulated EMT and metastasis via CCL11/CCR3[161]. Interestingly, primary melanoma cells recruited MDSCs via CXCL5. Consequently, recruited MDSCs promoted EMT and cancer cell dissemination via TGF β , EGF and HGF[152]. Similarly, breast cancer cells were reported to attract MDSCs via CCL3 production. Reciprocally, infiltrated MDSCs promoted EMT and metastasis by activating the PI3K-Akt-mTOR pathway in cancer cells, suggesting a positive feedback loop between MDSCs recruitment and tumor progression[162]. In summary, tumor cells could secrete GM-CSF, IL-6, CXCL5 or CCL3 to promote MDSCs recruitment and maturation. Reciprocally, infiltrated MDSCs stimulate EMT by secreting TGF- β , EGF, HGF, IL-6(target STAT3), IL-10, IL-28(target IFN- λ), NO (target NOTCH), NOS2 or CCL11(target AKT and ERK) (Fig. 2). The crosstalk between cancer cells and their surrounding stromal cells plays a critical role in EMT regulation, thereby impacting tumor progression and metastasis.

2.3. Hypoxia in EMT regulation

Tumor hypoxia is strongly associated with tumor progression, metastasis, and poor clinical outcomes. Hypoxia inducible factors (HIF), including HIF-1 α and HIF-2 α , are the main mediators of hypoxia responses. HIF target genes are involved in glycolysis, apoptosis, cell proliferation, angiogenesis and metastasis[163,164]. Hypoxia plays a major role in EMT regulation during tumor progression (Fig. 3).

2.3.1. Hypoxia promotes EMT via upregulating EMT transcription factors—

Hypoxia is shown to upregulate SNAI1/SNAI2 directly or indirectly in various cell types [165] via multiple mechanisms. Several studies revealed that HIF-1 α or HIF-2 α could directly regulate SNAI1 and SNAI2 transcriptionally[166–169] [179–182]. In human hepatocellular carcinoma and pancreatic cancer cells, HIF-1 α binds to SNAI1 at the –541 hypoxia-response element (HRE) site and promotes SNAI1 transcription to induce EMT[167–169]. Zhang et al. also reported that HIF-1 α could directly induce SNAI2 transcription to promote EMT through direct binding to the HRE sequence located in its proximal promoter in HNSCC cells [170]. Hypoxia is also shown to indirectly regulate SNAI1 expression via uPAR or USP47[171,172] to mediate hypoxia-induced EMT in breast cancer cells. Upregulation of uPAR during hypoxia activates the downstream PI3K-AKT signaling, thereby stimulating SNAI1 expression and EMT [171]. Ubiquitin-specific protease 47 (USP47), a deubiquitinating enzyme, promotes SNAI1 protein stabilization through deubiquitylation. Choi et al. reported that HIF-1 α indirectly enhances USP47 expression via SOX9 during hypoxia-induced EMT in colorectal cancer cells[172]. Hypoxia is also found to stimulate SNAI1 expression via the Notch pathway. Inhibition of Notch signaling abrogated hypoxia-induced SNAI1 upregulation and EMT in breast cancer cells and ovarian cancer cells [173,174]. ROS produced during hypoxia was shown to promote SNAI1 nuclear translocation via GSK-3 β inactivation and stimulated EMT in various cancer cell lines [175]. Regulation of SNAI2 by hypoxia was reported via HIF-1 α repressing miR-30c, leading to increased SNAI2 expression and EMT[176] in human renal cell carcinomas.

Hypoxia is also shown to stimulate TWIST1/TWIST2 expression in various cancer cells. HIF-1 α directly upregulated TWIST1 expression by binding to the HRE sequence in the proximal TWIST1 promoter in hypopharyngeal cancer, breast cancer and lung cancer cell lines [177]. Similarly, HIF-2 α directly induced TWIST1 transcription in cervix carcinoma, prostate cancer and colon cancer cell lines [178]. Prognostic analysis show that co-expression of either two factors among HIF-1 α /TWIST1/SNAI1 correlates with poor recurrence-free survival in NSCLC patients[179].

Both ZEB1 and ZEB2 are also frequently upregulated by hypoxia in different cancer cell lines. In colorectal cancer cells, Zhang et al. reported that HIF-1 α could directly induce ZEB1 expression by binding to the HRE sequence in the ZEB1 proximal promoter [180]. ZEB1 inhibition could significantly abrogate hypoxia-induced EMT and metastasis [180]. Similarly, hypoxia-induced ZEB1 upregulation led to cell migration and invasion in glioblastoma multiforme (GBM) cells [181, 182]. Indirect regulation of ZEB1 by hypoxia are also observed in multiple studies. In breast cancer cells, hypoxia repressed DICER expression epigenetically to reduce the miR- 16 – 200 level, promoting ZEB1 expression and subsequent EMT [183]. Su et al. reported that increased MEF2D expression in response to hypoxia directly regulated ZEB1 transcription through acetylation of ZEB1 promoter, leading to EMT in colorectal cancer cells[184]. LncRNA was also shown to regulate ZEB1 expression during hypoxia. LncRNA-BX111887 was highly upregulated during hypoxia and recruited YB1 to the ZEB1 promoter, enabling cells to undergo EMT in pancreatic cancer cells[185]. Zhang et al. found that LncRNA-HOTTIP acted as a sponge of miR-101 to stimulate ZEB1 mediated EMT in glioma cells[186]. Interestingly, hypoxia also promoted ZEB2–natural antisense transcript expression to increase ZEB2 translation efficiency[187].

These studies provide strong evidence that hypoxia regulates key EMT transcription factors, such as SNAI1/2, TWIST1/2 and ZEB1/2, to induce EMT in human cancer.

2.3.2. Hypoxia induces EMT via several signaling pathways including TGF β , EGFR, Notch and Hedgehog pathway—The TGF β pathway can be activated by hypoxia in various cancer cell lines. In gastric cancer cells, Matsuoka et al. showed that hypoxia upregulated TGF β 1 and TGF β R to stimulate the autocrine TGF β /TGF β R signaling, resulting in EMT in diffuse-type gastric cancer cells[188]. Similarly, in lung epithelial cells, hypoxia was shown to stimulate EMT via TGF- β 1 production, which is dependent on ROS production and HIF- α accumulation[189]. Additionally, HIF-1 α directly regulates transcription of TGF β 1 and TGF β 3 through binding to the HREs in their promoters, thereby leading to TGF β -induced EMT[190,191]. Several papers also suggest indirect regulation of the TGF β signaling by hypoxia, as the hypoxia-stimulated unfolded-protein response boosted TGF β expression in gastric cancer cells[192]. Similarly, Nagpal et al. found that miR-191 upregulation by HIF-1 α /HIF-2 α could increase TGF β 2 levels directly or indirectly through repressing HuR in breast cancer cells [193].

Hypoxia stimulates Notch signaling by increasing both Notch receptor and ligand levels in various cancer cell lines. Upon ligand binding, the active Notch intracellular domain (NICD) could directly upregulate SNAI1/2 transcription to promote EMT [173,194,195]. In ovarian cancer cells, Sahlgren et al. found that hypoxia increased the expression levels of

the Notch ligand DLL1 and NICD, thereby leading to SNAI1-mediated EMT[173]. NICD directly activates SNAI1 transcription through binding to the CSL motif in proximal to its promoter[173]. Notch receptor Notch3 and ligand DLL1, JAG1 and JAG2 levels were shown to be upregulated by hypoxia to facilitate EMT in breast cancer cells[174,196,197]. Du et al. found that hypoxia could indirectly increase expression of the Notch receptor Notch1 and the Notch ligand Jagged1 through suppressing miR-34a to promote EMT[198].

The Hedgehog (Hh) signaling also plays important roles in hypoxia-mediated EMT [199–201]. Activated GLI1 was shown to be responsible for upregulation of EMT-TFs, such as SNAI1/2 and TWIST1[202]. In particular, SNAI1 and TWIST1 were shown to be direct targets of GLI1 in hepatocellular carcinoma cells[203,204]. A study in mice shows that hypoxia could activate Hh signaling through HIF-1 α mediated Shh upregulation[205]. Similarly, increased transcription of Shh, SMO and GLI1 level or GLI1 nuclear translocation by HIF-1 α are also reported to facilitate EMT in various cancer cell lines[200,206]. Interestingly, in cholangiocarcinoma cells, HIF-1 α -mediated Shh activation not only provoked EMT, but also increased cancer stemness[206]. Treatment with an Shh inhibitor, cyclopamine, attenuated Shh activation with substantial abrogation of EMT and stemness[206]. HIF-1 α also triggered ligand-independent Hh signaling in pancreatic cancer cells, where hypoxia activated GLI1 directly and GLI1 depletion was sufficient to abrogate hypoxia-mediated EMT [201]. Moreover, Liu et al. found that HIF-1 α regulated non-canonical Hh through ROS production, which facilitated GLI1-dependent EMT and invasion in hepatocellular carcinomas[207].

Hypoxia also activates EGFR signaling to facilitate EMT. Hypoxia promotes EMT by upregulating EGFR expression in many cancer types, including HNSCC, glioma, gastric cancer, breast cancer and lung cancer [206–210]. Recent studies suggest that HIF-1 α directly regulates EGFR transcription through binding to the HRE sequence in EGFR intron 18 in breast cancer cells[211]. Moreover, EGFR translation efficiency was upregulated by hypoxia, whereby HIF-2 α boosted EGFR protein synthesis and drove autonomous proliferation in glioma cells[209]. Additionally, EGF is shown to be upregulated by hypoxia to facilitate malignant progression in various cancer types[210,212]. In hepatocellular carcinoma cells, HIF-2 α induced TGF- α and promoted EGFR activation under hypoxia [213,214].

In summary, hypoxia in the tumor microenvironment could impinge on a number of EMT-inducing signaling pathways to promote tumor invasion and metastasis.

3. EMT in cancer therapy resistance

3.1. EMT in chemoresistance

Increasing evidence shows that EMT plays a key role in chemoresistance in various human cancer types. Residual breast cancers often displayed a mesenchymal phenotype after chemotherapy in various human cancers[215]. The mesenchymal state induced by EMT confers drug resistance to many types of therapeutic agents. In Cyclophosphamide (CTX)-treated tumor-bearing mice, more than 60% of the surviving tumor cells presented a mesenchymal phenotype, indicating that mesenchymal tumor cells are more resistant

to chemotherapy[216]. Doxorubicin could activate the TGF- β signaling and EMT to promote breast cancer stem-like properties and drug resistance[217]. Chemotherapy in combination with TGF- β signaling inhibitors increased therapeutic efficacy and reduced chemoresistance[218]. Inhibition of ZEB1 has been shown to reverse EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell lines[219].

The EMT program confers therapy resistance via several mechanisms. Overexpression of EMT transcription factors is reported to increase the expression of ABC transporters, as expression of ABC transporters in breast cancer cells showed 10-fold more resistance to doxorubicin treatment compared with the control cells[220]. Activation of EMT also strongly induced expression of the AXL receptor tyrosine kinase in breast cancer cells[221]. Expression of the AXL receptor tyrosine kinase in carcinoma cells confers resistance to EGFR inhibitors on EGFR-mutant non-small-cell lung carcinoma (NSCLC) cells[222], thus Axl inhibition restored sensitivity to the EGFR inhibitor Erlotinib [223].

The EMT program has been shown to inhibit apoptosis to promote therapy resistance. EMT activation diminishes E-cadherin-mediated clustering of the TRAIL receptors DR4 and DR5, thereby making carcinoma cells resistant to TRAIL-induced apoptosis[224]. SNAI1 confers resistance against multiple apoptosis-inducing stimuli, in part by promoting AKT activation, upregulating the expression of the pro-survival protein Bcl-XL and delaying cell-cycle progression[225]. SNAI1 was also shown to confer chemoresistance by reducing the expression of p53 in carcinoma cells through interactions between SNAI1 and p53, thus allowing SNAG domain-associated HDAC1 to deacetylate p53[226]. SNAI2 blocks p53-mediated transcriptional induction of Encoding Bcl-2-binding Component 3 (BBC3) expression by directly repressing the BBC3 promoter region. Multiple lung adenocarcinoma cell lines acquire cisplatin resistance through AKT/NF- κ B/Slug-mediated BBC3 reduction [227,228].

Cancer stem cells (CSCs) are a subpopulation of neoplastic cells with stem-cell properties. EMT has been shown to be a critical regulator for the induction and maintenance of CSC properties[229]. CSCs are less sensitive to various chemotherapeutic drugs, including doxorubicin, cisplatin, paclitaxel, temozolomide, and methotrexate[59–64] and contribute to tumor recurrence after drug treatment. Given the critical role of EMT in cancer therapy resistance, understanding the signaling pathways induced by EMT will provide additional drug targets to sensitize cancer cells to chemotherapy.

3.2. EMT in immunotherapy resistance

Numerous studies suggest that EMT is highly associated with an immunosuppressive microenvironment. For example, EMT is correlated with high expression levels of immune checkpoint proteins, including PD-L1, PD-L2, PD-1, TIM-3, B7-H3, BTLA, and CTLA-4, in NSCLC cells [230]. Similarly, the expression levels of CTLA-4/PD-1/PD-L1/TIM-3/LAG-3 were highly associated with MMP-13/TWIST1 in ESCC patients[231]. Additionally, higher Tregs infiltration, M2 macrophage polarization and lower CD8 + T cells were reported to correlate with EMT in ovarian cancer, prostate cancer and NSCLCs[230,232,233]. Interestingly, Hugo et al. found that upregulation of EMT-related gene sets correlated with resistance to anti-PD-1 therapy in melanoma patients[234].

EMT transcription factors contribute to immunotherapy resistance via multiple mechanisms. In melanoma cells, SNAI1-induced EMT was shown to promote Tregs infiltration and impair dendritic cells by secreting TSP1[235]. Akalay et al. found that SNAI1-induced mesenchymal breast cancer cells exhibited resistance to CTL-mediated lysis via autophagy activation[236]. In an aPKC α -induced EMT model, SNAI1 was upregulated by aPKC α /Sp1 to drive EMT, resulting in the induction of immunosuppressive Tregs partially via IL-2 and TGF β production [237]. Additionally, Taki et al. demonstrated that high SNAI1 expressing tumors secreted high level of CXCL1 and CXCL2 chemokines via NF- κ B activation, leading to MDSCs recruitment and CD8⁺ infiltrating lymphocytes repression[238]. In breast cancer cells, cell surface expression of PD-L1 was shown to be stimulated by SNAI1 via post-translational upregulation of CMTM6 and CMTM7, leading to immune evasion [239]. CD47 is a macrophage immune checkpoint protein that suppresses macrophage phagocytic activity[240]. Overexpression of SNAI1 or ZEB1 increased CD47 expression in breast cancer cells, which significantly protected tumor cells from macrophage attack[241]. SNAI1 and ZEB1 were shown to directly bind to two E-boxes in the CD47 promoter[241]. In the transgenic MMTV-PyMT mouse model of breast adenocarcinoma, SNAI1-high mesenchymal tumor cells exhibited increased Tregs infiltration and M2 macrophage polarization compared to SNAI1-low epithelial tumors. Interestingly, mesenchymal tumor cells that showed high resistance to anti-CTLA4 treatment also conferred epithelial tumor cells resistance to immune attack[242]. Furthermore, SNAI1-high quasi-mesenchymal cells secreted high levels of CD73, CSF1 and SPP1, resulting in M2 polarization of TAMs and T cell suppression. Mechanistically, SNAI1 ChIP-seq data showed that SNAI1 was able to bind to 89 immunomodulatory genes[243].

Similarly, ZEB1 also plays an important role in immunosuppression by regulating PD-L1. In breast cancer cells and NSCLC cells, ZEB1 upregulated PD-L1 expression via repressing miR-200[244,245]. Chen et al. showed that miR-200 directly repressed PD-L1 transcription by binding to miR-200 family seed sequences on its 3'UTR. Therefore, ZEB1/miR-200 axis promotes PD-L1 upregulation to facilitate CD8⁺ T cell exhaustion [244]. Recently, Guo et al. showed that ZEB1 directly induced PD-L1 and CD47 expression, both of which contain the ZEB1 binding E-box[246]. Thus, EMT in cancer cells leads to an immunosuppressive tumor microenvironment through various mechanisms, including T cell exhaustion and immune cell repression, that decreases the effectiveness of tumor immunotherapies.

4. Targeting EMT-inducing signals in the tumor microenvironment for cancer therapy

4.1. Targeting the extracellular matrix

Most of the currently available therapies targeting EMT are aimed at blocking upstream inducers of EMT. Several studies demonstrated that the extracellular matrix, many regulators of ECM stiffness, various mechanosensors, and mechanotransducers are all targetable. Numerous inhibitors against CD44, DDR, LOX/LOX2, integrins, and FAK have been developed and some have shown anticancer activities in preclinical studies (Table 1).

Increased collagen crosslinking increases matrix stiffness and promotes EMT. Using recombinant collagenases to remove collagen from tumor ECM has emerged as a potential therapeutic approach, as depleting extracellular collagen could normalize the tumor microenvironment and increase the drug delivery efficiency[272,273]. LOX-mediated collagen crosslinking is a major contributor to ECM stiffening that promotes EMT and breast tumor progression. CCT365623, a LOX inhibitor with great therapeutic promise[262], suppressed breast cancer growth and metastasis in mice[274]. LOXL2 is correlated with ECM formation and induction of EMT. Treatment with a small molecule inhibitor of LOXL2((2-Chloropyridin-4-yl) methanamine hydrochloride) reversed LOXL2-induced EMT and significantly decreased the invasive ability of cervical cancer cells[261].

Several types of collagen molecules bind to and activate the discoidin domain receptors (DDRs). DDR1 and DDR2 are overexpressed in many cancer types. Inhibition of DDR1 with an ATP-competitive small-molecule kinase inhibitor (7rh) inhibited peritoneal metastasis in gastric carcinoma. Inhibition of DDR1 by 7rh also hindered tumor development in pancreatic ductal adenocarcinoma[251,253]. The small molecule allosteric inhibitor of DDR2 WRG-28 is shown to efficiently disrupt DDR2 receptor–collagen ligand interaction and DDR-mediated tumor progression in preclinical tumor models[252]. Dasatinib, another DDR2 inhibitor, shows promising results in preclinical models of DDR2-positive head and neck squamous cell carcinoma[275]. The extracellular domain of CD44 contains binding sites for various ECM molecules such as hyaluronan, collagen, and fibronectin. Activation of CD44 downstream signaling is involved in EMT-induced tumor progression. Several CD44 blocking antibodies and peptides have been developed to target CD44[276,277]. RO5429083, one of the CD44 antibodies, just entered a Phase 1 clinical trial ([Clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01358903) identifier: [NCT01358903](https://clinicaltrials.gov/ct2/show/study/NCT01358903)).

Inhibition of the integrin function has been shown to lead to reduced metastatic burden in various animal tumor models. $\alpha V\beta 3$ and $\alpha V\beta 5$ expression is significantly upregulated during EMT. Cilengitide is an integrin $\alpha V\beta 3$ and $\alpha V\beta 5$ inhibitor that is well tolerated and demonstrated modest antitumor activity among recurrent GBM patients in a phase I study [263]. However, several recent clinical trials showed that selective integrin inhibitors did not reach expected efficacy[278]. Emerging studies therefore focused on targeting the integrin downstream signaling, especially focal adhesion kinase (FAK), an important cell signaling hub that is highly activated upon integrin activation. FAK inhibition is identified as a potential strategy to overcome chemotherapy resistance. FAK activation coupled with the WNT- β -catenin signaling sustained tumor growth by promoting cancer stem cell survival and platinum resistance[279]. Combing a small molecule inhibitor of FAK with carboplatin and paclitaxel for the treatment of platinum-resistant high-grade serous ovarian cancer is now entering a clinical trial [280, 281]. Defactinib (VS-6063) is a FAK inhibitor currently tested in patients with advanced solid tumors in multiple clinical trials ([Clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT04620330) identifier: [NCT04620330](https://clinicaltrials.gov/ct2/show/study/NCT04620330); [NCT02546531](https://clinicaltrials.gov/ct2/show/study/NCT02546531); [NCT03287271](https://clinicaltrials.gov/ct2/show/study/NCT03287271))[278,282]. Integrin-linked kinase is another mechanotransducer and a critical regulator of intracellular integrin signaling. Preclinical studies show that QLT-0267, an ILK inhibitor, presented anticancer activities in colon cancer [63,283].

4.2. Targeting stromal and immune cells

4.2.1. Targeting cancer-associated fibroblasts—Therapeutically targeting CAF-stimulated EMT has shown promises in cancer treatment. Multiple drugs are shown to impair CAFs-stimulated EMT by interfering with the IL-6/IL-6R signaling, including siltuximab, tocilizumab, retinoic acid (RA), somatostatin analog SOM230 (pasireotide), nab-paclitaxel (nab-PTX), and cucurbitacin I (JSI-124)[284–289]. Siltuximab, an IL-6 neutralizing antibody, is shown to inhibit IL-6-mediated EMT in cholangiocarcinoma cells and exhibited anti-tumor efficacy in a xenograft model with co-injection of CAFs and lung cancer cells [284,290]. Clinically, Siltuximab treatment contributed to stable disease in more than 50% of patients with metastatic renal cell carcinoma[291]. Tocilizumab, an IL-6R inhibitor, blocked paracrine pro-EMT effects of CAFs on breast cancer cells in vitro and in vivo[285]. Interestingly, Billah et al. found that SOM230 specifically impaired IL-6 expression in CAFs through repressing eIF4E-Binding Protein-1 (4E-BP1)-mediated protein synthesis in pancreatic cancer[287]. Bae et al. demonstrates that an AXL inhibitor BGB324 could significantly suppress CAFs-induced EMT in gastric cancer cells, where AXL was activated by CAFs-secreted GAS6[292]. Targeting SDF-1 or the CXCL12/CXCR4 axis is also a promising therapeutic strategy. AMD3100, a CXCR4 antagonist, was shown to prevent CAFs-induced EMT in pancreatic and prostate cancer cells[93,94]. Specifically, AMD3100 treatment blocked the CXCL12/CXCR4 axis and suppressed p38 kinase, leading to reduced EMT, invasion and lung metastasis in pancreatic cancer cells[94]. Another CXCR4 antagonist BL-804, combined with pembrolizumab, showed benefit in metastatic PDAC patients [293]. Inhibitors targeting TGF β signaling, such as SB431542 or pirfenidone, are also shown to abrogate CAFs-induced EMT in breast cancer cells [294]. PHA-665752, a c-Met kinase inhibitor, attenuated CAFs-stimulated migration, invasion and tumorigenesis in hepatocellular carcinoma [74](Table 2).

4.2.2. Targeting cancer-associated adipocytes—Several targeting strategies have also been developed to target cancer-associated adipocytes to inhibit EMT. Adiponectin, secreted from normal adipocytes and downregulated in cancer-associated adipocytes (CAAs), was shown to reverse EMT and impair migration and invasion in NSCLC cells[330]. Adiponectin analogue ADP335 was developed to mimic its function on tumor progression. In breast cancer or prostate cancer xenograft models, ADP335 treatment significantly repressed tumor progression by modulating AMPK, Akt, STAT3 and ERK1/2 signaling [295,296]. Targeting leptin is also showing promise in halting tumor progression. PEG-LPrA2, acting as a leptin receptor antagonist, significantly reduced tumor growth in breast cancer xenografts in mice by repressing ERK, AKT or VEGF upregulation [297,298]. Additionally, a FABP4 inhibitor BMS309403 was reported to efficiently inhibit adipocyte-mediated EMT and metastasis in cholangiocarcinoma[106]. Niclosamide treatment repressed adipocyte-induced EMT by inhibiting IL-6/STAT3 axis in breast cancer cells[299]. Depletion of ASCs by D-CAN, also effectively repressed obesity-mediated EMT and prostate tumor progression[111,300](Table 2).

4.2.3. Targeting lymphocytes—Targeting EMT induction in combinations with anti-PD-1/PD-L1 immunotherapies has shown improvement in the response to immuno-therapies in cancer patients. Multiple studies suggest that anti-TGF β treatment could inhibit EMT

and synergize with immunotherapy to boost immune response and attenuate tumor progression[301,302]. In chemically induced squamous cell carcinomas, α -PD-1 therapy not only inhibited tumor growth, but also provoked immunosuppressive Tregs and activated TGF β /pSMAD3 signaling in tumors, leading to EMT, while addition of anti-TGF β treatment attenuated EMT and alleviated α -PD-1 resistance[301]. Thus, the anti-TGF β /anti-PD-1 combination therapy significantly inhibited CCK168 tumors growth and promoted survival in mice[301]. Indeed, bifunctional molecules targeting both TGF β and PD-L1 exhibited higher anti-tumor efficiency than anti-TGF β or anti-PD-L1 monotherapy. M7824, an anti-PD-L1/ TGF β Trap fusion protein, was shown to revert EMT in vivo and in vitro in lung cancer models and to boost CD8⁺ T cell and NK cell responses in various cancers, thereby leading to tumor regression and longer survival in mice [303–306]. The M7824 phase I trial showed promising antitumor efficacy in advanced solid tumor patients[307]. More recently, YM101, a new bifunctional antibody against TGF β and PD-L1 was shown to inhibit EMT and revert immunosuppression in tumor-bearing mice [308]. In KRAS mutant lung cancer models, combination of a MEK inhibitor and anti-PD-L1 therapy inhibited tumor growth, but also led to therapy resistance by increasing CD4⁺ Th17 infiltration[309]. CD4⁺ Th17 is implicated in inducing EMT in tumor cells by secreting IL-17. Peng et al. demonstrated that anti-IL-17 in combination with a MEK inhibitor and an anti-PD-L1 antibody significantly reduced tumor metastasis and therapy resistance in tumor-bearing mice[309](Table 2).

4.2.4. Targeting macrophages—TAMs play critical roles in promoting EMT, invasion and metastasis. Numerous macrophages targeting therapies significantly impede tumor progression, including blocking macrophages recruitment, TAMs depletion and reprogramming macrophages polarization[130,331]. Several studies show that blocking the CCL2/CCR2 axis could repress macrophage recruitment. A CCL2 neutralization antibody significantly inhibited macrophage infiltration and tumor metastasis in tumor-bearing mice[131]. RDC018, a CCR2 antagonist, significantly inhibited hepatocellular carcinoma tumor growth and metastasis[310]. Depletion of TAMs could also be achieved through interfering with CSF-1/CSF-1R axis. RG7155, a monoclonal antibody targeting CSF-1 receptor (CSF-1R), could deplete M2 macrophages both in vitro and in vivo, reducing tumor burden in diffuse-type giant cell tumor (Dt-GCT) patients[313]. CSF-1R inhibitors BLZ945 and PLX3397 not only eliminated immunosuppressive M2-like cells, but also boosted T cell response, leading to tumor regression in glioma and pancreatic cancer models[311,312]. Reprogramming TAMs to anti-tumor macrophages has also been tested to induce tumor regression. Hagemann et al. demonstrated that NF- κ B inhibition reprogramed M2 macrophages to M1 macrophages and repressed tumor growth by increasing IL-12-dependent NK activity[332]. BAY11–7082, a NF- κ B inhibitor, was shown to repress TAMs-mediated EMT and stemness in bladder cancer cells by suppressing M2 polarization[139]. IPI-549, a specific PI3K γ inhibitor, switched immunosuppressive TAMs to immunostimulatory macrophages by activating NF- κ B and inhibiting PI3K γ /mTOR-S6K α -C/EBP β , facilitating spontaneous breast carcinoma regression and reduced lung metastasis[315]. Additionally, the cannabinoid receptor-2 agonist, JWH-015 was shown to repress M2 macrophage-stimulated EMT in NSCLC cells and inhibit tumor growth in mice[316](Table 2).

4.2.5. Targeting MDSCs—Similarly to TAMs, MDSCs were implicated to stimulate EMT and facilitate metastasis. Several approaches were developed to repress MDSC functions, including depleting MDSCs, inhibiting MDSC recruitment, repressing MDSC function and promoting MDSC differentiation [333,334]. CSF-1R, CCR5 and CXCR2 could be targeted to block MDSCs recruitment and revert the immunosuppressive tumor environment [323,322,324]. Blattner et al. demonstrated that the CCR5-Ig fusion protein treatment reduced MDSCs and Tregs infiltration, thereby impeding melanoma tumor progression[323]. Similarly, CSF-1R inhibitors, PLX647 and PLX5622, and CXCR2 inhibitor SX682 were also reported to block MDSCs recruitment, enhancing the response to T cell checkpoint immunotherapy[322,324]. Several compounds including the PDE5 inhibitor, the COX-2 inhibitor and triterpenoid CDDO-Me were reported to impair the immunosuppressive function of MDSCs [325–327]. For example, Sildenafil, a PDE5 inhibitor neutralized MDSC function, thereby facilitating CD8⁺ T cell activation and inhibiting tumor growth[325]. Song et al. show that Ginsenoside Rg3 blocked MDSC-mediated EMT and stemness acquisition in breast cancer cells by repressing Notch and STAT3 activation, resulting in tumor suppression [335](Table 2). Given these studies, targeting both TAMs and MDSCs in the tumor microenvironment could be a feasible approach to block tumor cell EMT and metastasis.

4.3. Targeting hypoxia

Hypoxia-mediated tumor malignant transformation is mainly orchestrated by HIF-1 α /HIF-2 α proteins. Numerous inhibitors targeting HIF-1 α /HIF-2 α were developed for potential cancer therapies, including 1) PX-478[336,337] that inhibits HIF-1 α transcription, translation and de-ubiquitination; 2) digoxin[338,339] and topotecan[340,341] that inhibit HIF-1 α /2 α protein synthesis; 3) acriflavine[342] that blocks HIF-1 α /2 α dimerization with HIF-1 β ; 4) 2-methoxyestradiol (2ME2) that inhibits HIF-1 α /2 α nuclear accumulation[343]; 5) echinomycin (NSC-13502) [344–346] that inhibits HIF-1 α binding to the HRE; 6) chetomin[347], bortezomib[348], YC-1[349], all of which inhibit HIF-1 α /2 α binding to its transactivator p300 (Table 3). PX-478 treatment efficiently suppressed tumor metastasis in HIF-1 α -expressing lung cancer cells[350]. Clinically, PX-478 treatment contributed to improved radiotherapy or chemotherapy efficacy in combination with anti-cancer drugs[351]. Digoxin is shown to prevent hypoxia-mediated EMT by blocking the HIF-1 α -ZEB1 axis, further repressing the migration and invasion capacity of GBM cells[182]. Moreover, Carmen et al. demonstrated that either digoxin or acriflavine significantly reduced lung metastasis in breast cancer xenografts in mice [352]. In glioma cells, echinomycin prevented hypoxia-induced EMT and invasion by repressing the HIF-1 α /miR-210/TGF- β and HIF-1 α /miR-210/NF- κ B axis, respectively[353]. Similarly, YC-1 treatment reduced hypoxia-induced migration and invasion, leading to metastasis suppression in hepatocellular carcinoma and breast cancer xenografts in mice[354,355].

HIF-2 α is a key oncogene in ccRCC, especially in VHL-deficient tumors, where stabilized HIF-2 α drives tumor invasion and metastasis [366]. Thus, multiple inhibitors specifically targeting HIF-2 α were designed to impair its oncogenic activity, such as THS-044[366], PT2385 (MK-3795)[362,363], PT2399[360,361] and belzutifan (MK-6482 or PT2977) [364](Table 3). These inhibitors significantly reduce HIF-2 α target gene expression

by interrupting its heterodimerization with HIF-1 β . PT2385 treatment was shown to inhibit HIF-2 α -induced expression of VEGF-A, PAI-1 and cyclin D1, thereby leading to tumor regression of the VHL-deficient ccRCC xenograft model [362]. Furthermore, tumor regression in 34% VHL-deficient ccRCC patients was reported in a phase I clinical study of patients with locally advanced or metastatic ccRCC[363]. Rui et al. developed the second generation HIF-2 α inhibitor, belzutifan, which significantly repressed HIF-2 α target erythropoietin (EPO) expression and promoted tumor regression in ccRCC bearing mice[364]. Belzutifan showed promising anti-tumor activity in metastatic ccRCC patients[365]. Additionally, belzutifan, in combination with cabozantinib, demonstrated to be an effective treatment for patients with metastatic ccRCC (NCT03634540) and has recently been approved by FDA for VHL-related diseases, including ccRCC tumors[367]. Although the action of HIF inhibition on tumor cells is pleiotropic, EMT is likely to be one of the key effects that can be targeted to inhibit metastasis and chemoresistance.

5. Conclusion

In this review, we summarized various important microenvironmental cues that impinge on the EMT program to impact tumor development, progression, and therapy response in human tumors, including ECM, hypoxia, stroma cells, and immune cells. Much has been learned from the past two decades of intensive research on EMT and the tumor microenvironment. First, the communication between the tumor microenvironment and the EMT program is not unidirectional. Instead, tumor cells that have undergone EMT can also modulate stromal cells, immune cells, and the ECM to generate a more tumor-prone tumor microenvironment to further facilitate tumor development and progression. Dissecting the bidirectional interactions between tumor cells and their microenvironment and their effects on EMT requires more innovative in vitro culture systems to better mimic the complex three-dimensional biochemical and biophysical tumor microenvironment. Second, the interaction between the tumor microenvironment and EMT is highly dynamic in time and space. As discussed above, the EMT program is a dynamic and transient program during tumor progression. While activation of the transient EMT program promotes tumor cell dissemination into distant organs, tumor cells undergo MET to regain growth at distant organs. Therefore, the same microenvironmental cues in primary tumors and distant organs may impact tumor progression differentially, which should be carefully considered in selecting targeted therapies. Third, extensive clinical and experimental data show a tight association between the mesenchymal state and resistance to various cancer therapeutics. Given many such therapies target cell proliferation, it is conceivable why the mesenchymal state with reduced proliferation is resistant to such therapeutics. However, EMT is also reported to provide resistance to numerous therapeutics, such as immunotherapies, that do not directly target cell proliferation. Elucidating how EMT provides resistance to various cancer therapeutics is critical for developing new approaches to overcome therapy resistance. Lastly, many therapeutic approaches that target tumor microenvironmental cues impact EMT and tumor progression, some of which showed promising clinical benefits in cancer patients. While EMT plays an important role in tumor metastasis, very few cancer therapeutics are designed for metastasis prevention. As our knowledge of EMT and metastasis continues to grow, it becomes evident that metastasis prevention will become

an effective approach for high-risk cancer survivors that are prone to developing metastatic recurrence. The EMT research could contribute significantly to the next generation of cancer therapeutics on metastasis prevention.

Acknowledgements

We apologize to many researchers whose work we were unable to cite due to space restrictions. Our research is supported by grants from NCI (1R01CA262794, 1R01CA174869, 1R01CA206880, and 1R01CA236386), CDMRP DOD Breast Cancer Program BC170283, METAvivor Research Award, California Tobacco-Related Disease Research Program, and AACR-Bayer Innovation and Discovery Grant. The study sponsors are not involved in the writing of the manuscript and the decision to submit the manuscript for publication.

Data Availability

No data was used for the research described in the article.

References

- [1]. Lambert AW, Weinberg RA, Linking EMT programmes to normal and neoplastic epithelial stem cells, *Nat. Rev. Cancer* 21 (2021) 325–338, 10.1038/s41568-021-00332-6. [PubMed: 33547455]
- [2]. Scott LE, Weinberg SH, Lemmon CA, Mechanochemical signaling of the extracellular matrix in epithelial-mesenchymal transition, *Front. Cell Dev. Biol* 7 (2019) 135, 10.3389/fcell.2019.00135. [PubMed: 31380370]
- [3]. Brabletz T, Kalluri R, Nieto MA, Weinberg RA, EMT in cancer, *Nat. Rev. Cancer* 18 (2018) 128–134, 10.1038/nrc.2017.118. [PubMed: 29326430]
- [4]. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S, Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition, *Science* 339 (2013) 580–584, 10.1126/science.1228522. [PubMed: 23372014]
- [5]. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, García de Herreros A, Goodall GJ, Hadjantonakis AK, Huang RJY, Kalcheim C, Kalluri R, Kang Y, Khew-Goodall Y, Levine H, Liu J, Longmore GD, Mani SA, Massagüe J, Mayor R, McClay D, Mostov KE, Newgreen DF, Nieto MA, Puisieux A, Runyan R, Savagner P, Stanger B, Stemmler MP, Takahashi Y, Takeichi M, Theveneau E, Thiery JP, Thompson EW, Weinberg RA, Williams ED, Xing J, Zhou BP, Sheng G, Guidelines and definitions for research on epithelial–mesenchymal transition, *Nat. Rev. Mol. Cell Biol* 21 (2020) 341–352, 10.1038/s41580-020-0237-9. [PubMed: 32300252]
- [6]. Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, Deschler DG, Varvares MA, Mylvaganam R, Rozenblatt-Rosen O, Rocco JW, Faquin WC, Lin DT, Regev A, Bernstein BE, Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer, *e24, Cell* 171 (2017) 1611–1624, 10.1016/j.cell.2017.10.044.
- [7]. Simeonov KP, Byrns CN, Clark ML, Norgard RJ, Martin B, Stanger BZ, Shendure J, McKenna A, Lengner CJ, Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states, *e9, Cancer Cell* 39 (2021) 1150–1162, 10.1016/j.ccell.2021.05.005. [PubMed: 34115987]
- [8]. Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Keymeulen AV, Brown D, Moers V, Lemaire S, Clercq SD, Minguíjón E, Balsat C, Sokolow Y, Dubois C, Cock FD, Scozzaro S, Sopena F, Lanas A, Haene ND, Salmon I, Marine J, Voet T, Sotiropoulou PA, Identification of the tumour transition states occurring during EMT, (2018).
- [9]. Pastushenko I, Blanpain C, EMT transition states during tumor progression and metastasis, *Trends Cell Biol.* 29 (2019) 212–226, 10.1016/j.tcb.2018.12.001. [PubMed: 30594349]

- [10]. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J, Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis, *Cancer Cell* 22 (2012) 725–736, 10.1016/j.ccr.2012.09.022. [PubMed: 23201165]
- [11]. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D, Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance, *Nature* 527 (2015) 472–476, 10.1038/nature15748. [PubMed: 26560033]
- [12]. Li Y, Lv Z, Zhang S, Wang Z, He L, Tang M, Pu W, Zhao H, Zhang Z, Shi Q, Cai D, Wu M, Hu G, Lui KO, Feng J, Nieto MA, Zhou B, Genetic fate mapping of transient cell fate reveals n-cadherin activity and function in tumor metastasis, *e5, Dev. Cell* 54 (2020) 593–607, 10.1016/j.devcel.2020.06.021.
- [13]. Bornes L, van Scheppingen RH, Beerling E, Schelfhorst T, Ellenbroek SIJ, Seinstra D, van Rheenen J, Fsp1-mediated lineage tracing fails to detect the majority of disseminating cells undergoing EMT, *e3, Cell Rep.* 29 (2019) 2565–2569, 10.1016/j.celrep.2019.10.107.
- [14]. Löönd F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F, Santacroce N, Beisel C, Ivanek R, Bürglin T, Tiede S, van Rheenen J, Christofori G, Distinct contributions of partial and full EMT to breast cancer malignancy, *e11, Dev. Cell* 56 (2021) 3203–3221, 10.1016/j.devcel.2021.11.006.
- [15]. Zhang J, Tian XJ, Zhang H, Teng Y, Li R, Bai F, Elankumaran S, Xing J, TGF- β -induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops, *Sci. Signal* 7 (2014) ra91, 10.1126/scisignal.2005304. [PubMed: 25270257]
- [16]. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, García De Herrerros A, The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells, 2000.
- [17]. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Angela Nieto M, The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression, 2000.
- [18]. Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, Cano A, The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors, *J. Cell Sci* 116 (2003) 499–511, 10.1242/jcs.00224. [PubMed: 12508111]
- [19]. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R, DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells, *Oncogene* 24 (2005) 2375–2385, 10.1038/sj.onc.1208429. [PubMed: 15674322]
- [20]. Comijn J, Berx G, Vermassen P, Verschuere K, Van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, Van Roy F, The Two-Handed E Box Binding Zinc Finger Protein SIP1 Downregulates E-Cadherin and Induces Invasion made clear that aberrant E-cadherin expression, re-sulting from somatic inactivating mutations of both E-cadherin alleles, is rare and so far largely confined to diffuse gastric carcinomas and infiltrative lobular breast carcinomas (Becker et al., 2001).
- [21]. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA, Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis, *Cell* 117 (2004) 927–939, 10.1016/j.cell.2004.06.006. [PubMed: 15210113]
- [22]. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromental C, Puisieux A, Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence, *Cancer Cell* 14 (2008) 79–89, 10.1016/j.ccr.2008.06.005. [PubMed: 18598946]
- [23]. Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, Yang CJ, Yuan L, Ouyang G, Twist2 contributes to breast cancer progression by promoting an epithelialmesenchymal transition and cancer stem-like cell self-renewal, *Oncogene* 30 (2011) 4707–4720, 10.1038/onc.2011.181. [PubMed: 21602879]
- [24]. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L, Yang J, Twist1-induced invadopodia formation promotes tumor metastasis, *Cancer Cell* 19 (2011) 372–386, 10.1016/j.ccr.2011.01.036. [PubMed: 21397860]

- [25]. Nowak E, Bednarek I, Aspects of the epigenetic regulation of emt related to cancer metastasis, *Cells* 10 (2021), 10.3390/cells10123435.
- [26]. Addison JB, Voronkova MA, Fugett JH, Lin CC, Linville NC, Trinh B, Livengood RH, Smolkin MB, Schaller MD, Ruppert JM, Pugacheva EN, Creighton CJ, Ivanov AV, Functional hierarchy and cooperation of emt master transcription factors in breast cancer metastasis, *Mol. Cancer Res* 19 (2021) 784–798, 10.1158/1541-7786.MCR-20-0532. [PubMed: 33500360]
- [27]. Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ, Yang J, Snail2 is an essential mediator of twist1-induced epithelial mesenchymal transition and metastasis, *Cancer Res.* 71 (2011) 245–254, 10.1158/0008-5472.CAN-10-2330. [PubMed: 21199805]
- [28]. Korpala M, Lee ES, Hu G, Kang Y, The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2, *J. Biol. Chem* 283 (2008) 14910–14914, 10.1074/jbc.C800074200. [PubMed: 18411277]
- [29]. Park SM, Gaur AB, Lengyel E, Peter ME, The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2, *Genes Dev.* 22 (2008) 894–907, 10.1101/gad.1640608. [PubMed: 18381893]
- [30]. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ, The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1, *Nat. Cell Biol* 10 (2008) 593–601, 10.1038/ncb1722. [PubMed: 18376396]
- [31]. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T, A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells, *EMBO Rep.* 9 (2008) 582–589, 10.1038/embor.2008.74. [PubMed: 18483486]
- [32]. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, Hausen AZ, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T, The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs, *Nat. Cell Biol* 11 (2009) 1487–1495, 10.1038/ncb1998. [PubMed: 19935649]
- [33]. Siemens H, Jackstadt R, Hüntens S, Kaller M, Menssen A, Götz U, Hermeking H, miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions, *Cell Cycle* 10 (2011) 4256–4271, 10.4161/cc.10.24.18552. [PubMed: 22134354]
- [34]. Xu J, Lamouille S, Derynck R, TGF- β -induced epithelial to mesenchymal transition, *Cell Res.* 19 (2009) 156–172, 10.1038/cr.2009.5.
- [35]. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Müller GA, Strutz F, Kalluri R, Renal fibrosis, *Am. J. Pathol* 159 (2001) 1313–1321, 10.1016/S0002-9440(10)62518-7. [PubMed: 11583959]
- [36]. Gong Y, Yang Y, Activation of Nrf2/AREs-mediated antioxidant signalling, and suppression of profibrotic TGF- β 1/Smad3 pathway: a promising therapeutic strategy for hepatic fibrosis — a review, *Life Sci.* 256 (2020), 10.1016/j.lfs.2020.117909.
- [37]. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ, Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor- β signaling, *Am. J. Respir. Cell Mol. Biol* 38 (2008) 95–104, 10.1165/rcmb.2007-0071OC. [PubMed: 17673689]
- [38]. Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW, Keely PJ, Longmore GD, The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis, *Nat. Cell Biol* 15 (2013) 677–687, 10.1038/ncb2743. [PubMed: 23644467]
- [39]. Griggs LA, Hassan NT, Malik RS, Griffin BP, Martinez BA, Elmore LW, Lemmon CA, Fibronectin fibrils regulate TGF- β 1-induced Epithelial-Mesenchymal Transition, *Matrix Biol.* 60–61 (2017) 157–175, 10.1016/j.matbio.2017.01.001.
- [40]. Park J, Schwarzbauer JE, Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition, *Oncogene* 33 (2014) 1649–1657, 10.1038/ncb.2013.118. [PubMed: 23624917]
- [41]. Bourguignon LYW, Singleton PA, Zhu H, Zhou B, Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor β receptor i in metastatic breast tumor cells, *J. Biol. Chem* 277 (2002) 39703–39712, 10.1074/jbc.M204320200. [PubMed: 12145287]
- [42]. El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, Campagne A, Toner M, Bhatia SN, Irimia D, Vincent-Salomon A, Karnoub AE, Critical

- role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy, *Proc. Natl. Acad. Sci. U. S. A* 109 (2012) 17460–17465, 10.1073/pnas.1206653109. [PubMed: 23033492]
- [43]. Matrisian LM, The matrix-degrading metalloproteinases, *Bioessays* 14 (1992) 455–463, 10.1002/bies.950140705. [PubMed: 1445287]
- [44]. Aimes RT, Quigley JP, Matrix Metalloproteinase-2 Is an Interstitial Collagenase, *J. Biol. Chem* 270 (1995) 5872–5876, 10.1074/jbc.270.11.5872. [PubMed: 7890717]
- [45]. Song W, Jackson K, McGuire PG, Degradation of Type IV collagen by matrix metalloproteinases is an important step in the epithelial-mesenchymal transformation of the endocardial cushions, *Dev. Biol* 227 (2000) 606–617, 10.1006/dbio.2000.9919. [PubMed: 11071778]
- [46]. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Angela Nieto M, Werb Z, Bissell MJ, Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability, *Nature* 436 (2005) 123–127, 10.1038/nature03688. [PubMed: 16001073]
- [47]. Siegel RC, Fu JCC, Uto N, Horiuchi K, Fujimoto D, Collagen cross-linking: lysyl oxidase dependent synthesis of pyridinoline in vitro: Confirmation that pyridinoline is derived from collagen, *Biochem. Biophys. Res. Commun* 108 (1982) 1546–1550, 10.1016/S0006-291X(82)80083-1. [PubMed: 6129847]
- [48]. Csiszar K, Lysyl oxidases: a novel multifunctional amine oxidase family, (2001).
- [49]. Peinado H, del M Carmen Iglesias-de la Cruz, D. Olmeda, K. Csiszar, K.S.K. Fong, S. Vega, M.A. Nieto, A. Cano, F. Portillo, A molecular role for lysyl oxidase-like 2 enzyme in Snail regulation and tumor progression, *EMBO J.* 24 (2005) 3446–3458, 10.1038/sj.emboj.7600781. [PubMed: 16096638]
- [50]. Boufraqech M, Zhang L, Nilubol N, Sadowski SM, Kotian S, Quezado M, Kebebew E, Lysyl oxidase (LOX) transcriptionally regulates SNAI2 expression and TIMP4 secretion in human cancers, *Clin. Cancer Res* 22 (2016) 4491–4504, 10.1158/1078-0432.CCR-15-2461. [PubMed: 27029493]
- [51]. Schietke R, Warnecke C, Wacker I, Schödel J, Mole DR, Campean V, Amann K, Goppelt-Struebe M, Behrens J, Eckardt K-U, Wiesener MS, The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress e-cadherin in hypoxia, *J. Biol. Chem* 285 (2010) 6658–6669, 10.1074/jbc.M109.042424. [PubMed: 20026874]
- [52]. Kechagia JZ, Ivaska J, Roca-Cusachs P, Integrins as biomechanical sensors of the microenvironment, *Nat. Rev. Mol. Cell Biol* 20 (2019) 457–473, 10.1038/s41580-019-0134-2. [PubMed: 31182865]
- [53]. Jang I, Beningo KA, Integrins, CAFs and mechanical forces in the progression of cancer, *Cancers* 11 (2019), 10.3390/cancers11050721.
- [54]. Hamidi H, Ivaska J, Every step of the way: Integrins in cancer progression and metastasis, *Nat. Rev. Cancer* 18 (2018) 533–548, 10.1038/s41568-018-0038-z. [PubMed: 30002479]
- [55]. Wei SC, Fattat L, Tsai JH, Guo Y, Pai VH, Majeski HE, Chen AC, Sah RL, Taylor SS, Engler AJ, Yang J, Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway, *Nat. Cell Biol* 17 (2015) 678–688, 10.1038/ncb3157. [PubMed: 25893917]
- [56]. Guo W, Giancotti FG, Integrin signalling during tumour progression, *Nat. Rev. Mol. Cell Biol* 5 (2004) 816–826, 10.1038/nrm1490. [PubMed: 15459662]
- [57]. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, Aldape K, Landers DV, Carpenter W, Gillett N, Sheppard D, Matthay MA, Albelda SM, Kramer RH, Pytela R, Expression of the $\beta 6$ integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling, (n.d.) 11.
- [58]. Truong HH, Xiong J, Ghotra VPS, Nirmala E, Haazen L, Le Dévédec SE, Balciolu HE, He S, Snaar-Jagalska BE, Vreugdenhil E, Meerman JHN, van de Water B, Danen EHJ, $\beta 1$ integrin inhibition elicits a prometastatic switch through the TGF β –miR-200–ZEB network in E-cadherin–positive triple-negative breast cancer, *Sci. Signal* 7 (2014), 10.1126/scisignal.2004751.
- [59]. Xu H, Bihan D, Chang F, Huang PH, Farndale RW, Leitinger B, Discoidin domain receptors promote $\alpha 1\beta 1$ - and $\alpha 2\beta 1$ -integrin mediated cell adhesion to collagen by enhancing integrin activation, *PLoS One* 7 (2012), e52209, 10.1371/journal.pone.0052209. [PubMed: 23284937]

- [60]. Przybyla L, Muncie JM, Weaver VM, Mechanical control of epithelial-to-mesenchymal transitions in development and cancer, *Annu. Rev. Cell Dev. Biol* 32 (2016) 527–554, 10.1146/annurev-cellbio-111315-125150. [PubMed: 27298087]
- [61]. Gálvez BG, Matías-Román S, Yáñez-Mó M, Sánchez-Madrid F, Arroyo AG, ECM regulates MT1-MMP localization with $\beta 1$ or $\alpha v\beta 3$ integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells, *J. Cell Biol* 159 (2002) 509–521, 10.1083/jcb.200205026. [PubMed: 12427871]
- [62]. Cao J, Chiarelli C, Richman O, Zarrabi K, Kozarekar P, Zucker S, Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer, *J. Biol. Chem* 283 (2008) 6232–6240, 10.1074/jbc.M705759200. [PubMed: 18174174]
- [63]. Chadla P, Arbi M, Nikou S, Kalliakoudas T, Papadaki H, Taraviras S, Lygerou Z, Bravou V, Integrin-linked-kinase overexpression is implicated in mechanisms of genomic instability in human colorectal cancer, *Dig. Dis. Sci* 66 (2021) 1510–1523, 10.1007/s10620-020-06364-6. [PubMed: 32495257]
- [64]. Górska A, Mazur AJ, Integrin-linked kinase (ILK): the known vs. the unknown and perspectives, *Cell. Mol. Life Sci* 79 (2022), 10.1007/s00018-021-04104-1.
- [65]. Kilinc AN, Han S, Barrett LA, Anandasivam N, Nelson CM, Integrin-linked kinase tunes cell-cell and cell-matrix adhesions to regulate the switch between apoptosis and EMT downstream of TGF $\beta 1$, *Mol. Biol. Cell* 32 (2021) 402–412, 10.1091/mbc.E20-02-0092. [PubMed: 33405954]
- [66]. Bae C, Sachs F, Gottlieb PA, The mechanosensitive ion channel Piezo1 is inhibited by the peptide GsMTx4, *Biochemistry* 50 (2011) 6295–6300, 10.1021/bi200770q. [PubMed: 21696149]
- [67]. Li Y, Xu C, Sun B, Zhong F, Cao M, Yang L, Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF - β signaling by recruiting Rab5c, *Cancer Cell Int.* (2022) 1–19, 10.1186/s12935-022-02574-2. [PubMed: 34980127]
- [68]. Kärki T, Tojkander S, Trpv protein family—from mechanosensing to cancer invasion, *Biomolecules* 11 (2021) 1–23, 10.3390/biom11071019.
- [69]. Azimi I, Robitaille M, Armitage K, So CL, Milevskiy MJG, Northwood K, Lim HF, Thompson EW, Roberts-Thomson SJ, Monteith GR, Activation of the ion channel TRPV4 induces epithelial to mesenchymal transition in breast cancer cells, *Int. J. Mol. Sci* 21 (2020) 1–14, 10.3390/ijms21249417.
- [70]. Wei SC, Fattet L, Yang J, The forces behind EMT and tumor metastasis, *Cell Cycle* 14 (2015) 2387–2388, 10.1080/15384101.2015.1063296. [PubMed: 26083471]
- [71]. Jung HY, Fattet L, Yang J, Molecular pathways: linking tumor microenvironment to Epithelial-mesenchymal transition in metastasis, *Clin. Cancer Res* 21 (2015) 962–968, 10.1158/1078-0432.CCR-13-3173. [PubMed: 25107915]
- [72]. Fattet L, Jung H-Y, Matsumoto MW, Aubol BE, Kumar A, Adams JA, Chen AC, Sah RL, Engler AJ, Pasquale EB, Yang J, Matrix rigidity controls epithelial-mesenchymal plasticity and tumor metastasis via a mechanoresponsive EPHA2/LYN complex, *e7, Dev. Cell* 54 (2020) 302–316, 10.1016/j.devcel.2020.05.031.
- [73]. Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM, Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF- β signalling, *Br. J. Cancer* 110 (2014) 724–732, 10.1038/bjc.2013.768. [PubMed: 24335925]
- [74]. Lau EYT, Lo J, Cheng BYL, Ma MKF, Lee JMF, Ng JKY, Chai S, Lin CH, Tsang SY, Ma S, Ng IOL, Lee TKW, Cancer-associated fibroblasts regulate tumor-initiating cell plasticity in hepatocellular carcinoma through c-Met/FRA1/HEY1 signaling, *Cell Rep.* 15 (2016) 1175–1189, 10.1016/j.celrep.2016.04.019. [PubMed: 27134167]
- [75]. Sun Y, Fan X, Zhang Q, Shi X, Xu G, Zou C, Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling, *Tumor Biol.* 39 (2017) 1–10, 10.1177/1010428317712592.
- [76]. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, *Cell* 121 (2005) 335–348, 10.1016/j.cell.2005.02.034. [PubMed: 15882617]

- [77]. Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, Li J, Li C, Yan M, Zhu Z, Liu B, Su L, IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway, *Oncotarget* 8 (2017) 20741–20750, 10.18632/oncotarget.15119. [PubMed: 28186964]
- [78]. Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M, Qin Y, Sun K, Teng Y, Liu M, Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β 3–p38 MAPK signalling, *Cancer Lett.* 442 (2019) 320–332, 10.1016/j.canlet.2018.10.015. [PubMed: 30391782]
- [79]. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E, MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer, *Cancer Discov.* 2 (2012) 1100–1108, 10.1158/2159-8290.CD-12-0206. [PubMed: 23171795]
- [80]. Soon PSH, Kim E, Pon CK, Gill AJ, Moore K, Spillane AJ, Benn DE, Baxter RC, Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells, *Endocr. -Relat. Cancer* 20 (2013) 1–12, 10.1530/ERC-12-0227. [PubMed: 2311755]
- [81]. Yu B, Chen X, Li J, Qu Y, Su L, Peng Y, Huang J, Yan J, Yu Y, Gu Q, Zhu Z, Liu B, Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression, *BMC Cell Biol.* 14 (2013), 10.1186/1471-2121-14-17.
- [82]. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P, Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness, *Cancer Res.* 70 (2010) 6945–6956, 10.1158/0008-5472.CAN-10-0785. [PubMed: 20699369]
- [83]. Luga V, Zhang L, Vilorio-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL, Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration, *Cell* 151 (2012) 1542–1556, 10.1016/j.cell.2012.11.024. [PubMed: 23260141]
- [84]. Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C, Rienzo A, Piscuoglio S, Thomas R, Condorelli G, Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer, *Oncotarget* 8 (2017) 19592–19608, 10.18632/oncotarget.14752. [PubMed: 28121625]
- [85]. Zhang J, Tian XJ, Xing J, Signal transduction pathways of EMT induced by TGF- β , SHH, and WNT and their crosstalks, *J. Clin. Med* 5 (2016) 1–18, 10.3390/jcm5040041.
- [86]. Zhuang J, Lu Q, Shen B, Huang X, Shen L, Zheng X, Huang R, Yan J, Guo H, TGF β 1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT, *Sci. Rep* 5 (2015) 1–13, 10.1038/srep11924.
- [87]. Dongre A, Weinberg RA, New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer, *Nat. Rev. Mol. Cell Biol* 20 (2019), 10.1038/s41580-018-0080-4.
- [88]. Hua W, ten Dijke P, Kostidis S, Giera M, Hornsveld M, TGF β -induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer, *Cell. Mol. Life Sci* 77 (2020) 2103–2123, 10.1007/s00018-019-03398-6. [PubMed: 31822964]
- [89]. Derynck R, Turley SJ, Akhurst RJ, TGF β biology in cancer progression and immunotherapy, *Nat. Rev. Clin. Oncol* 18 (2021) 9–34, 10.1038/s41571-020-0403-1. [PubMed: 32710082]
- [90]. Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, Bolduc S, Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling, *BMC Cancer* 19 (2019) 1–13, 10.1186/s12885-019-5353-6. [PubMed: 30606139]
- [91]. Jia C, Wang G, Wang T, Fu B, Zhang Y, Huang L, Deng Y, Chen G, Wu X, Chen J, Pan Y, Tai Y, Liang J, Li X, Hu K, Xie B, Li S, Yang Y, Chen G, Zhang Q, Liu W, Cancer-associated fibroblasts induce epithelial-mesenchymal transition via the transglutaminase 2-dependent il-6/il6r/stat3 axis in hepatocellular carcinoma, *Int. J. Biol. Sci* 16 (2020) 2542–2558, 10.7150/ijbs.45446.
- [92]. Wang L, Zhang F, Cui JY, Chen L, Chen YT, Liu BW, CAFs enhance paclitaxel resistance by inducing EMT through the IL-6/JAK2/STAT3 pathway, *Oncol. Rep* 39 (2018) 2081–2090, 10.3892/or.2018.6311. [PubMed: 29565447]

- [93]. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H, Wang J, Jin T, Zhang H, Dai J, Krebsbach PH, Keller ET, Pienta KJ, Taichman RS, Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis, *Nat. Commun* 4 (2013) 1–11, 10.1038/ncomms2766.
- [94]. Li D, Qu C, Ning Z, Wang H, Zang K, Zhuang L, Chen L, Wang P, Meng Z, Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts, *Am. J. Cancer Res* 6 (2016) 2192–2206. [PubMed: 27822411]
- [95]. Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio IIC, Hwang CI, Tiriach H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA, Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer, *J. Exp. Med* 214 (2017) 579–596, 10.1084/jem.20162024. [PubMed: 28232471]
- [96]. Costa A, Kieffer Y, Scholer-dahirel A, Soumelis V, Vincent-salomon A, Costa A, Kieffer Y, Scholer-dahirel A, Pelon F, Bourachot B, Cardon M, Fibroblast heterogeneity and immunosuppressive environment in human breast cancer article fibroblast heterogeneity and immunosuppressive environment in human breast cancer, *e10, Cancer Cell* 33 (2018) 463–479, 10.1016/j.ccell.2018.01.011.
- [97]. Mosa MH, Michels BE, Menche C, Nicolas AM, Darvishi T, Greten FR, Farin HF, A wnt-induced phenotypic switch in cancer-associated fibroblasts inhibits EMT in colorectal cancer, *Cancer Res.* 80 (2020) 5569–5582, 10.1158/0008-5472.CAN-20-0263. [PubMed: 33055221]
- [98]. Lengyel E, Makowski L, DiGiovanni J, Kolonin MG, Cancer as a matter of fat: the crosstalk between adipose tissue and tumors, *Trends Cancer* 4 (2018) 374–384, 10.1016/j.trecan.2018.03.004. [PubMed: 29709261]
- [99]. Walter M, Liang S, Ghosh S, Hornsby PJ, Li R, Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells, 2009 28:30. 28, *Oncogene* (2009) 2745–2755, 10.1038/onc.2009.130. [PubMed: 19483720]
- [100]. Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S, Garrido I, Escourrou G, Valet P, Muller C, Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion, *Cancer Res.* 71 (2011) 2455–2465, 10.1158/0008-5472.CAN-10-3323. [PubMed: 21459803]
- [101]. Gyamfi J, Lee YH, Eom M, Choi J, Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells, 2018 8:1. 8, *Sci. Rep* (2018) 1–13, 10.1038/s41598-018-27184-9. [PubMed: 29311619]
- [102]. Wei L, Li K, Pang X, Guo B, Su M, Huang Y, Wang N, Ji F, Zhong C, Yang J, Zhang Z, Jiang Y, Liu Y, Chen T, Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2, *J. Exp. Clin. Cancer Res. CR* 35 (2016), 10.1186/S13046-016-0446-4.
- [103]. Al-Khalaf HH, Amir M, Al-Mohanna F, Tulbah A, Al-Sayed A, Aboussekhra A, Obesity and p16 INK4A downregulation activate breast adipocytes and promote their protumorigenicity, *Mol. Cell. Biol* 37 (2017), 10.1128/mcb.00101-17.
- [104]. Haque I, Ghosh A, Acup S, Banerjee S, Dhar K, Ray A, Sarkar S, Kambhampati S, Banerjee SK, Leptin-induced ER- α -positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway, *BMC Cancer* 18 (2018) 1–14, 10.1186/S12885-018-3993-6/FIGURES/7. [PubMed: 29291726]
- [105]. Park J, Scherer PE, Adipocyte-derived endotrophin promotes malignant tumor progression, *J. Clin. Investig* 122 (2012) 4243–4256, 10.1172/JCI63930. [PubMed: 23041627]
- [106]. Nie J, Zhang J, Wang L, Lu L, Yuan Q, An F, Zhang S, Jiao Y, Adipocytes promote cholangiocarcinoma metastasis through fatty acid binding protein 4, *J. Exp. Clin. Cancer Res* 36 (2017) 1–15, 10.1186/S13046-017-0641-Y/FIGURES/9.
- [107]. Xu Q, Wang L, Li H, Han Q, Li J, Qu X, Huang S, Zhao RC, Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF- β , *Int. J. Oncol* 41 (2012) 959–968, 10.3892/ijo.2012.1541. [PubMed: 22766682]
- [108]. Wu S, Wang Y, Yuan Z, Wang S, Du H, Liu X, Wang Q, Zhu X, Human adipose-derived mesenchymal stem cells promote breast cancer MCF7 cell epithelial-mesenchymal transition by

cross interacting with the TGF- β /Smad and PI3K/AKT signaling pathways, *Mol. Med. Rep* 19 (2019) 177–186, 10.3892/mmr.2018.9664. [PubMed: 30483746]

- [109]. D'esposito V, Liguoro D, Ambrosio MR, Collina F, Cantile M, Spinelli R, Raciti GA, Miele C, Valentino R, Campiglia P, De Laurentiis M, Di Bonito M, Botti G, Franco R, Beguinot F, Formisano P, Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5, n.d. <www.impactjournals.com/oncotarget/> .
- [110]. Song X, Zhou X, Qin Y, Yang J, Wang Y, Sun Z, Yu K, Zhang S, Liu S, Emodin inhibits epithelial-mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC-chemokine ligand 5 secreted from adipocytes, *Int. J. Mol. Med* 42 (2018) 579–588, 10.3892/ijmm.2018.3638. [PubMed: 29693154]
- [111]. Su F, Daquinag AC, Ahn S, Saha A, Dai Y, Zhao Z, DiGiovanni J, Kolonin MG, Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium, *npj Precis. Oncol* 5 (2021), 10.1038/s41698-021-00160-9.
- [112]. Yan D, Avtanski D, Saxena NK, Sharma D, Leptin-induced epithelialmesenchymal transition in breast cancer cells requires β -catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways, *J. Biol. Chem* 287 (2012) 8598–8612, 10.1074/jbc.M111.322800. [PubMed: 22270359]
- [113]. Chang CC, Wu MJ, Yang JY, Camarillo IG, Chang CJ, Leptin-STAT3-G9a signaling promotes obesity-mediated breast cancer progression, *Cancer Res.* 75 (2015) 2375–2386, 10.1158/0008-5472.CAN-14-3076. [PubMed: 25840984]
- [114]. Villanueva-Duque A, Daniela Zuniga-Eulogio M, Dena-Beltran J, Castaneda Saucedo E, Calixto-Galvez M, Mendoza-Catalán MA, Ortuno-Pineda C, Navarro-Tito N, Leptin induces partial epithelial-mesenchymal transition in a FAKERK dependent pathway in MCF10A mammary non-tumorigenic cells, 2017. <www.ijcep.com/> .
- [115]. Olea-Flores M, Juárez-Cruz JC, Mendoza-Catalán MA, Padilla-Benavides T, Navarro-Tito N, Signaling pathways induced by leptin during epithelial–mesenchymal transition in breast cancer, *Int. J. Mol. Sci Vol.* 19 (2018) 3493, 10.3390/IJMS19113493. [PubMed: 30404206]
- [116]. Jin J, Zhang Z, Zhang S, Chen X, Chen Z, Hu P, Wang J, Xie C, Fatty acid binding protein 4 promotes epithelial-mesenchymal transition in cervical squamous cell carcinoma through AKT/GSK3 β /Snail signaling pathway, *Mol. Cell. Endocrinol* 461 (2018) 155–164, 10.1016/j.mce.2017.09.005. [PubMed: 28893569]
- [117]. Xie Q, Ding J, Chen Y, Role of CD8+ T lymphocyte cells: Interplay with stromal cells in tumor microenvironment, *Acta Pharm. Sin. B* 11 (2021) 1365–1378, 10.1016/j.apsb.2021.03.027. [PubMed: 34221857]
- [118]. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H, Concurrent infiltration by CD8+ T cells and CD4 + T cells is a favourable prognostic factor in non-small-cell lung carcinoma, *Br. J. Cancer* 94 (2006) 275–280, 10.1038/sj.bjc.6602934. [PubMed: 16421594]
- [119]. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay NEH, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E, Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers, *Clin. Cancer Res* 12 (2006) 465–472, 10.1158/1078-0432.CCR-05-1886. [PubMed: 16428488]
- [120]. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JMS, Mahmoud SMA, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PDP, Caldas C, Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients, *Ann. Oncol* 25 (2014) 1536–1543, 10.1093/annonc/mdu191. [PubMed: 24915873]
- [121]. Xu X, Tan Y, Qian Y, Xue W, Wang Y, Du J, Jin L, Ding W, Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: a meta-analysis, *Medicine* 98 (2019), 10.1097/MD.00000000000013923.
- [122]. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CCS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L, Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer, *e13, Cell* 181 (2020) 1612–1625, 10.1016/j.cell.2020.05.017.

- [123]. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL, Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells, *Cancer Res.* 69 (2009) 2887–2895, 10.1158/0008-5472.CAN-08-3343. [PubMed: 19276366]
- [124]. Goebel L, Grage-Griebenow E, Gorys A, Helm O, Genrich G, Lenk L, Wesch D, Ungefroren H, Freitag-Wolf S, Sipos B, Röcken C, Schäfer H, Sebens S, CD4+ T cells potently induce epithelial-mesenchymal- transition in premalignant and malignant pancreatic ductal epithelial cells—novel implications of CD4+ T cells in pancreatic cancer development, *OncoImmunology* 4 (2015), 10.1080/2162402X.2014.1000083.
- [125]. Salazar Y, Zheng X, Brunn D, Raifer H, Picard F, Zhang Y, Winter H, Guenther S, Weigert A, Weigmann B, Dumoutier L, Renauld JC, Waisman A, Schmall A, Tufman A, Fink L, Brüne B, Bopp T, Grimminger F, Seeger W, Pullamsetti SS, Huber M, Savai R, Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer, *J. Clin. Investig* 130 (2020) 3560–3575, 10.1172/JCI124037. [PubMed: 32229721]
- [126]. Xiong S, Pan X, Xu L, Yang Z, Guo R, Gu Y, Li R, Wang Q, Xiao F, Du L, Zhou P, Zhu M, Regulatory T cells promote β -catenin-mediated epithelium-to-mesenchyme transition during radiation-induced pulmonary fibrosis, *Int. J. Radiat. Oncol. Biol. Phys* 93 (2015) 425–435, 10.1016/j.ijrobp.2015.05.043. [PubMed: 26253394]
- [127]. Shi C, Chen Y, Chen Y, Yang Y, Bing W, Qi J, Cd4 + cd25 + regulatory t cells promote hepatocellular carcinoma invasion via $\text{tgf-}\beta$ 1-induced epithelial–mesenchymal transition, *OncoTargets Ther* 12 (2019) 279–289, 10.2147/OTT.S172417.
- [128]. Oh E, Hong J, Yun C-O, Regulatory T cells induce metastasis by increasing $\text{Tgf-}\beta$ and enhancing the epithelial–mesenchymal transition, *Cells* 8 (2019) 1387, 10.3390/cells8111387. [PubMed: 31690033]
- [129]. Yang J, Li Y, Sun Z, Zhan H, Macrophages in pancreatic cancer: An immunometabolic perspective, *Cancer Lett.* 498 (2021) 188–200, 10.1016/j.canlet.2020.10.029. [PubMed: 33122097]
- [130]. Tan Y, Wang M, Zhang Y, Ge S, Zhong F, Xia G, Sun C, Tumor-associated macrophages: a potential target for cancer therapy, *Front. Oncol* 11 (2021) 1–17, 10.3389/fonc.2021.693517.
- [131]. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW, CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis, *Nature* 475 (2011) 222–225, 10.1038/nature10138. [PubMed: 21654748]
- [132]. Su S, Liu Q, Chen J, Chen J, Chen F, He C, Huang D, Wu W, Lin L, Huang W, Zhang J, Cui X, Zheng F, Li H, Yao H, Su F, Song E, A Positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis, *Cancer Cell* 25 (2014) 605–620, 10.1016/j.ccr.2014.03.021. [PubMed: 24823638]
- [133]. Fan QM, Jing YY, Yu GF, Kou XR, Ye F, Gao L, Li R, Zhao QD, Yang Y, Lu ZH, Wei LX, Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma, *Cancer Lett* 352 (2014) 160–168, 10.1016/j.canlet.2014.05.008. [PubMed: 24892648]
- [134]. Fu XT, Dai Z, Song K, Zhang ZJ, Zhou ZJ, Zhou SL, Zhao YM, Xiao YS, Sun QM, Ding ZB, Fan J, Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway, *Int. J. Oncol* 46 (2015) 587–596, 10.3892/ijo.2014.2761. [PubMed: 25405790]
- [135]. Yeung OWH, Lo CM, Ling CC, Qi X, Geng W, Li CX, Ng KTP, Forbes SJ, Guan XY, Poon RTP, Fan ST, Man K, Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma, *J. Hepatol* 62 (2015) 607–616, 10.1016/j.jhep.2014.10.029. [PubMed: 25450711]
- [136]. Zhang J, Yan Y, Yang Y, Wang L, Li M, Wang J, Liu X, Duan X, Wang J, High infiltration of tumor-associated macrophages influences poor prognosis in human gastric cancer patients, associates with the phenomenon of EMT, *Medicine* 95 (2016) 1–6, 10.1097/MD.0000000000002636.
- [137]. Gao L, Zhang W, Zhong WQ, Liu ZJ, Li HM, Yu ZL, Zhao YF, Tumor associated macrophages induce epithelial to mesenchymal transition via the EGFR/ERK1/2 pathway in head and neck

- squamous cell carcinoma, *Oncol. Rep* 40 (2018) 2558–2572, 10.3892/or.2018.6657. [PubMed: 30132555]
- [138]. Gao S, Hu J, Wu X, Liang Z, PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3/ERK-dependent activation of Wnt/ β -catenin signaling pathway, *Biomed. Pharmacother* 108 (2018) 618–624, 10.1016/j.biopha.2018.09.067. [PubMed: 30243096]
- [139]. Zhang Q, Mao Z, Sun J, NF- κ B inhibitor, BAY11–7082, suppresses M2 tumor-associated macrophage induced EMT potential via miR-30a/NF- κ B/Snail signaling in bladder cancer cells, *Gene* 710 (2019) 91–97, 10.1016/j.gene.2019.04.039. [PubMed: 31002892]
- [140]. Xie Y, Chen Z, Zhong Q, Zheng Z, Chen Y, Shangguan W, Zhang Y, Yang J, Zhu D, Xie W, M2 macrophages secrete CXCL13 to promote renal cell carcinoma migration, invasion, and EMT, *Cancer Cell Int.* 21 (2021) 1–13, 10.1186/s12935-021-02381-1. [PubMed: 33397383]
- [141]. Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA, Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors, *BMC Cancer* 12 (2012), 10.1186/1471-2407-12-35.
- [142]. Bates RC*, Mercurio AM, Tumor necrosis factor- α stimulates the epithelial-to-mesenchymal transition of human colonic organoids, *Mol. Biol. Cell* 14 (2003) 1790–1800, 10.1091/mbc.E02. [PubMed: 12802055]
- [143]. Dehai C, Bo P, Qiang T, Lihua S, Fang L, Shi J, Jingyan C, Yan Y, Guangbin W, Zhenjun Y, Enhanced invasion of lung adenocarcinoma cells after co-culture with THP-1-derived macrophages via the induction of EMT by IL-6, *Immunol. Lett* 160 (2014) 1–10, 10.1016/j.imlet.2014.03.004. [PubMed: 24698728]
- [144]. Liu CY, Xu JY, Shi XY, Huang W, Ruan TY, Xie P, Ding JL, M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway, *Lab. Invest* 93 (2013) 844–854, 10.1038/labinvest.2013.69. [PubMed: 23752129]
- [145]. Ding J, Yang C, Zhang Y, Wang J, Zhang S, Guo D, Yin T, Yang J, M2 macrophage-derived G-CSF promotes trophoblasts EMT, invasion and migration via activating PI3K/Akt/Erk1/2 pathway to mediate normal pregnancy, *J. Cell. Mol. Med* 25 (2021) 2136–2147, 10.1111/jcmm.16191. [PubMed: 33393205]
- [146]. Kawata M, Koinuma D, Ogami T, Umezawa K, Iwata C, Watabe T, Miyazono K, TGF- β -induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells, *J. Biochem* 151 (2012) 205–216, 10.1093/jb/mvr136. [PubMed: 22161143]
- [147]. Zhu L, Fu X, Chen X, Han X, Dong P, M2 macrophages induce EMT through the TGF- β /Smad2 signaling pathway, *Cell Biol. Int* 41 (2017) 960–968, 10.1002/cbin.10788. [PubMed: 28493530]
- [148]. Che D, Zhang S, Jing Z, Shang L, Jin S, Liu F, Shen J, Li Y, Hu J, Meng Q, Yu Y, Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/ β -catenin signalling pathway, *Mol. Immunol* 90 (2017) 197–210, 10.1016/j.molimm.2017.06.018. [PubMed: 28837884]
- [149]. Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, Liu Q, Dou R, Xiong B, Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis, *Mol. Cancer* 18 (2019) 1–23, 10.1186/s12943-019-0976-4. [PubMed: 30609930]
- [150]. Safarzadeh E, Orangi M, Mohammadi H, Babaie F, Baradaran B, Myeloid-derived suppressor cells: important contributors to tumor progression and metastasis, *J. Cell. Physiol* 233 (2018) 3024–3036, 10.1002/jcp.26075. [PubMed: 28661031]
- [151]. Kumar V, Patel S, Tcyganov E, Gabrilovich DI, The nature of myeloid-derived suppressor cells in the tumor microenvironment, *Trends Immunol.* 37 (2016) 208–220, 10.1016/j.it.2016.01.004. [PubMed: 26858199]
- [152]. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, Kato M, PrevostBlondel A, Thiery JP, Abastado JP, Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor, *PLoS Biol.* 9 (2011), 10.1371/journal.pbio.1001162.

- [153]. Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, Denardo DG, Goedegebuure SP, Linehan DC, Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer, *Cancer Immunol., Immunother* 63 (2014) 513–528, 10.1007/s00262-014-1527-x. [PubMed: 24652403]
- [154]. Li ZL, Ye SB, OuYang LY, Zhang H, Chen YS, He J, Chen QY, Qian CN, Zhang XS, Cui J, Zeng YX, Li J, COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells, *OncoImmunology* 4 (2015), 10.1080/2162402X.2015.1044712.
- [155]. Ouzounova M, Lee E, Piranlioglu R, El Andaloussi A, Kolhe R, Demirci MF, Marasco D, Asm I, Chadli A, Hassan KA, Thangaraju M, Zhou G, Arbab AS, Cowell JK, Korkaya H, Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade, *Nat. Commun* 8 (2017), 10.1038/ncomms14979.
- [156]. Fu X-G, Deng J, Xu W-J, Chen J-Y, Sun J, Deng H, Histidine decarboxylase-expressing PMN-MDSC-derived TGF- β 1 promotes the epithelial-mesenchymal transition of metastatic lung adenocarcinoma, *Int. J. Clin. Exp. Pathol* 13 (2020) 1361–1371. [PubMed: 32661471]
- [157]. Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanislawek A, Polkowski W, Kurylcio A, Kleer C, Chang AE, Wicha M, Sabel M, Zou W, Kryczek I, Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling, *Cancer Res.* 76 (2016) 3156–3165, 10.1158/0008-5472.CAN-15-2528. [PubMed: 27197152]
- [158]. Zhu H, Gu Y, Xue Y, Yuan M, Cao X, Liu Q, CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion, *Oncotarget* 8 (2017) 114554–114567, 10.18632/oncotarget.23020. [PubMed: 29383101]
- [159]. Mucha J, Majchrzak K, Taciak B, Hellmén E, Król M, MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN- λ) signaling, *PLoS ONE* 9 (2014) 1–11, 10.1371/journal.pone.0103249.
- [160]. Ma X, Wang M, Yin T, Zhao Y, Wei X, Myeloid-derived suppressor cells promote metastasis in breast cancer after the stress of operative removal of the primary cancer, *Front. Oncol* 9 (2019) 1–11, 10.3389/fonc.2019.00855. [PubMed: 30761267]
- [161]. Lin S, Zhang X, Huang G, Cheng L, Lv J, Zheng D, Lin S, Wang S, Wu Q, Long Y, Li B, Wei W, Liu P, Pei D, Li Y, Wen Z, Cui S, Li P, Sun X, Wu Y, Yao Y, Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells, *Oncogene* 40 (2021) 1476–1489, 10.1038/s41388-020-01605-4. [PubMed: 33452453]
- [162]. Luo A, Meng M, Wang G, Han R, Zhang Y, Jing X, Zhao L, Gu S, Zhao X, Myeloid-derived suppressor cells recruited by chemokine (C-c motif) ligand 3 promote the progression of breast cancer via phosphoinositide 3-kinase-protein kinase b-mammalian target of rapamycin signaling, *J. Breast Cancer* 23 (2020) 141–161, 10.4048/jbc.2020.23.e26. [PubMed: 32395374]
- [163]. Ikeda H, Kakeya H, Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy, *J. Antibiot* 74 (2021) 687–695, 10.1038/s41429-021-00451-0.
- [164]. Hapke RY, Haake SM, Hypoxia-induced epithelial to mesenchymal transition in cancer, *Cancer Lett.* 487 (2020) 10–20, 10.1016/j.canlet.2020.05.012. [PubMed: 32470488]
- [165]. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T, Konishi I, Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells, *Am. J. Pathol* 163 (2003) 1437–1447, 10.1016/S0002-9440(10)63501-8. [PubMed: 14507651]
- [166]. Luo D, Wang J, Li J, Post M, Mouse snail is a target gene for HIF, *Mol. Cancer Res* 9 (2011) 234–245, 10.1158/1541-7786.MCR-10-0214. [PubMed: 21257819]
- [167]. Zhang L, Huang G, Li X, Zhang Y, Jiang Y, Shen J, Liu J, Wang Q, Zhu J, Feng X, Dong J, Qian C, Hypoxia induces epithelial-mesenchymal transition via activation of SNAIL by hypoxia-inducible factor -1 α in hepatocellular carcinoma, *BMC Cancer* 13 (2013) 24–27, 10.1186/1471-2407-13-108. [PubMed: 23327652]

- [168]. Zhu GH, Huang C, Feng ZZ, Lv XH, Qiu ZJ, Hypoxia-induced snail expression through transcriptional regulation by HIF-1 α in pancreatic cancer cells, *Dig. Dis. Sci* 58 (2013) 3503–3515, 10.1007/s10620-013-2841-4. [PubMed: 23979441]
- [169]. Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, Zeisberg EM, Snail Is a direct target of hypoxia-inducible factor 1 α (HIF1 α) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells, *J. Biol. Chem* 290 (2015) 16553–16664, 10.1074/jbc.M115.636944.
- [170]. Zhang J, Cheng Q, Zhou Y, Wang Y, Chen X, Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: Correlations with poor prognosis, *Oral. Oncol* 49 (2013) 1043–1050, 10.1016/j.oraloncology.2013.08.003. [PubMed: 24035721]
- [171]. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL, uPAR induces epithelialmesenchymal transition in hypoxic breast cancer cells, *J. Cell Biol* 178 (2007) 425–436, 10.1083/jcb.200701092. [PubMed: 17664334]
- [172]. Choi BJ, Park SA, Lee SY, Cha YN, Surh YJ, Hypoxia induces epithelialmesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 47-mediated stabilization of Snail: a potential role of Sox9, *Sci. Rep* 7 (2017) 1–15, 10.1038/s41598-017-15139-5. [PubMed: 28127051]
- [173]. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U, Notch signaling mediates hypoxia-induced tumor cell migration and invasion, *Proc. Natl. Acad. Sci. USA* 105 (2008) 6392–6397, 10.1073/pnas.0802047105. [PubMed: 18427106]
- [174]. Chen J, Imanaka N, Chen J, Griffin JD, Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion, *Br. J. Cancer* 102 (2010) 351–360, 10.1038/sj.bjc.6605486. [PubMed: 20010940]
- [175]. Cannito S, Novo E, Compagnone A, di Bonzo LV, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A, Bozzo F, Cravanzola C, Bravoco V, Colombatto S, Parola M, Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells, *Carcinogenesis* 29 (2008) 2267–2278, 10.1093/carcin/bgn216. [PubMed: 18791199]
- [176]. Huang J, Yao X, Zhang J, Dong B, Chen Q, Xue W, Liu D, Huang Y, Hypoxia-induced downregulation of miR-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma, *Cancer Sci.* 104 (2013) 1609–1617, 10.1111/cas.12291. [PubMed: 24112779]
- [177]. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ, Direct regulation of TWIST by HIF-1 α promotes metastasis, *Nat. Cell Biol* 10 (2008) 295–305, 10.1038/ncb1691. [PubMed: 18297062]
- [178]. Gort EH, Van Haaften G, Verlaan I, Groot AJ, Plasterk RHA, Shvarts A, Suijkerbuijk KPM, Van Laar T, Van Der Wall E, Raman V, Van Diest PJ, Tijsterman M, Vooijs M, The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2 α , *Oncogene* 27 (2008) 1501–1510, 10.1038/sj.onc.1210795. [PubMed: 17873906]
- [179]. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ, Prognostic significance of hypoxia-inducible factor-1 α , TWIST1 and Snail expression in resectable non-small cell lung cancer, *Thorax* 64 (2009) 1082–1089, 10.1136/thx.2009.115691. [PubMed: 19778933]
- [180]. Zhang W, Shi X, Peng Y, Wu M, Zhang P, Xie R, Wu Y, Yan Q, Liu S, Wang J, HIF-1 α promotes epithelial-mesenchymal transition and metastasis through direct regulation of ZEB1 in colorectal cancer, *PLoS One* 10 (2015) 1–16, 10.1371/journal.pone.0129603.
- [181]. Kahlert UD, Suwala AK, Raabe EH, Siebzehrubl FA, Suarez MJ, Orr BA, Bar EE, Maciaczyk J, Eberhart CG, ZEB1 promotes invasion in human fetal neural stem cells and hypoxic glioma neurospheres, *Brain Pathol* 25 (2015) 724–732, 10.1111/bpa.12240. [PubMed: 25521330]
- [182]. Joseph JV, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, Balasubramanian V, Wagemakers M, den Dunnen WFA, Kruyt FAE, Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1 α -ZEB1 axis, *Cancer Lett.* 359 (2015) 107–116, 10.1016/j.canlet.2015.01.010. [PubMed: 25592037]
- [183]. Van Den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S, Starmans MHW, Yao CQ, Ivan M, Ivan C, Pecot CV, Boutros PC, Sood AK, Koritzinsky M, Wouters BG, Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER, *Nat. Commun* 5 (2014), 10.1038/ncomms6203.

- [184]. Su L, Luo Y, Yang Z, Yang J, Yao C, Cheng F, Shan J, Chen J, Li F, Liu L, Liu C, Xu Y, Jiang L, Guo D, Prieto J, Avila MA, Shen J, Qian C, MEF2D transduces microenvironment stimuli to ZEB1 to promote epithelial-mesenchymal transition and metastasis in colorectal cancer, *Cancer Res.* 76 (2016) 5054–5067, 10.1158/0008-5472.CAN-16-0246. [PubMed: 27364559]
- [185]. Deng SJ, Chen HY, Ye Z, Deng SC, Zhu S, Zeng Z, He C, Liu ML, Huang K, Zhong JX, Xu FY, Li Q, Liu Y, Wang CY, Zhao G, Hypoxia-induced LncRNA-bx111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription, *Oncogene* 37 (2018) 5811–5828, 10.1038/s41388-018-0382-1. [PubMed: 29970904]
- [186]. Zhang S, Wang W, Liu G, Xie S, Li Q, Li Y, Lin Z, Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis, *Biomed. Pharmacother* 95 (2017) 711–720, 10.1016/j.biopha.2017.08.133. [PubMed: 28886531]
- [187]. Nakuluri K, Mukhi D, Nishad R, Saleem MA, Mungamuri SK, Menon RK, Pasupulati AK, Hypoxia induces ZEB2 in podocytes: Implications in the pathogenesis of proteinuria, *J. Cell. Physiol* 234 (2019) 6503–6518, 10.1002/jcp.27387. [PubMed: 30238984]
- [188]. Matsuoka J, Yashiro M, Doi Y, Fuyuhiko Y, Kato Y, Shinto O, Noda S, Kashiwagi S, Aomatsu N, Hirakawa T, Hasegawa T, Shimizu K, Shimizu T, Miwa A, Yamada N, Sawada T, Hirakawa K, Hypoxia Stimulates the EMT of Gastric Cancer Cells through Autocrine TGF β Signaling, *PLoS One* 8 (2013), 10.1371/journal.pone.0062310.
- [189]. Zhou G, Dada LA, Wu M, Kelly A, Trejo H, Zhou Q, Varga J, Sznajder JI, Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1, *Am. J. Physiol. Lung Cell. Mol. Physiol* 297 (2009) 1120–1130, 10.1152/ajplung.00007.2009.
- [190]. Schäffer L, Scheid A, Spielmann P, Breyman C, Zimmermann R, Meuli M, Gassmann M, Marti HH, Wenger RH, Oxygen-regulated expression of TGF- β 3, a growth factor involved in trophoblast differentiation, *Placenta* 24 (2003) 941–950, 10.1016/S0143-4004(03)00166-8. [PubMed: 14580376]
- [191]. Hung SP, Yang MH, Tseng KF, Lee OK, Hypoxia-induced secretion of TGF-b1 in mesenchymal stem cell promotes breast cancer cell progression, *Cell Transplant.* 22 (2013) 1869–1882, 10.3727/096368912X657954. [PubMed: 23067574]
- [192]. Shen X, Xue Y, Si Y, Wang Q, Wang Z, Yuan J, Zhang X, The unfolded protein response potentiates epithelial-to-mesenchymal transition (EMT) of gastric cancer cells under severe hypoxic conditions, *Med. Oncol* 32 (2015) 1–7, 10.1007/s12032-014-0447-0.
- [193]. Nagpal N, Ahmad HM, Chameettachal S, Sundar D, Ghosh S, Kulshreshtha R, HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGF β -signaling in hypoxic microenvironment, *Sci. Rep* 5 (2015) 1–14, 10.1038/srep09650.
- [194]. Niessen K, Fu YX, Chang L, Hoodless PA, McFadden D, Karsan A, Slug is a direct Notch target required for initiation of cardiac cushion cellularization, *J. Cell Biol* 182 (2008) 315–325, 10.1083/jcb.200710067. [PubMed: 18663143]
- [195]. Cho ES, Kang HE, Kim NH, Yook JI, Therapeutic implications of cancer epithelial-mesenchymal transition EMT, *Arch. Pharmacol Res* 42 (2019) 14–24, 10.1007/s12272-018-01108-7.
- [196]. Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W, Pandey PR, Fukuda K, Hirota S, Sugai T, Wakabayashi G, Koeda K, Kashiwaba M, Suzuki K, Chiba T, Endo M, Mo YY, Watabe K, Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells, *Oncogene* 30 (2011) 4075–4086, 10.1038/onc.2011.122. [PubMed: 21499308]
- [197]. Ishida T, Hijioka H, Kume K, Miyawaki A, Nakamura N, Notch signaling induces EMT in OSCC cell lines in a hypoxic environment, *Oncol. Lett* 6 (2013) 1201–1206, 10.3892/ol.2013.1549. [PubMed: 24179495]
- [198]. Du R, Sun W, Xia L, Zhao A, Yu Y, Zhao L, Wang H, Huang C, Sun S, Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells, *PLoS One* 7 (2012), 10.1371/journal.pone.0030771.
- [199]. Lei J, Fan L, Wei G, Chen X, Duan W, Xu Q, Sheng W, Wang K, Li X, Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer, *Tumor Biol* 36 (2015) 3119–3126, 10.1007/s13277-014-2948-z.

- [200]. Wang G, Zhang Z, Xu Z, Yin H, Bai L, Ma Z, DeCoster MA, Qian G, Wu G, Activation of the sonic hedgehog signaling controls human pulmonary arterial smooth muscle cell proliferation in response to hypoxia, *Biochim. Et. Biophys. Acta Mol. Cell Res* 1803 (2010) 1359–1367, 10.1016/j.bbamcr.2010.09.002.
- [201]. Lei J, Ma J, Ma Q, Li X, Liu H, Xu Q, Duan W, Sun Q, Xu J, Wu Z, Wu E, Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner, *Mol. Cancer* 12 (2013) 1–11, 10.1186/1476-4598-12-66. [PubMed: 23286373]
- [202]. Tang C, Mei L, Pan L, Xiong W, Zhu H, Ruan H, Zou C, Tang L, Iguchi T, Wu X, Hedgehog signaling through GLI1 and GLI2 is required for epithelialmesenchymal transition in human trophoblasts, *Biochim. Et. Biophys. Acta Gen. Subj* 1850 (2015) 1438–1448, 10.1016/j.bbagen.2015.04.005.
- [203]. Zheng X, Rumie Vittar NB, Gai X, Fernandez-Barrena MG, Moser CD, Hu C, Almada LL, McCleary-Wheeler AL, Elsawa SF, Vrabel AM, Shire AM, Comba A, Thorgeirsson SS, Kim Y, Liu Q, Fernandez-Zapico ME, Roberts LR, The transcription factor GLI1 mediates TGF β 1 driven EMT in hepatocellular carcinoma via a SNAI1-dependent mechanism, *PLoS ONE* 7 (2012), 10.1371/journal.pone.0049581.
- [204]. Li J, He Y, Cao Y, Yu Y, Chen X, Gao X, Hu Q, Upregulation of Twist is involved in Gli1 induced migration and invasion of hepatocarcinoma cells, *Biol. Chem* 399 (2018) 911–919, 10.1515/hsz-2018-0131. [PubMed: 29908118]
- [205]. Bijlsma MF, Groot AP, Oduro JP, Franken RJ, Schoenmakers SHHF, Peppelenbosch MP, Spek CA, Hypoxia induces a hedgehog response mediated by HIF-1 α , *J. Cell. Mol. Med* 13 (2009) 2053–2060, 10.1111/j.1582-4934.2008.00491.x. [PubMed: 18774959]
- [206]. Bhuria V, Xing J, Scholta T, Bui KC, Nguyen MLT, Malek NP, Bozko P, Plentz RR, Hypoxia induced Sonic Hedgehog signaling regulates cancer stemness, epithelial-to-mesenchymal transition and invasion in cholangiocarcinoma, *Exp. Cell Res* 385 (2019), 111671, 10.1016/j.yexcr.2019.111671. [PubMed: 31634481]
- [207]. Liu Z, Tu K, Wang Y, Yao B, Li Q, Wang L, Dou C, Liu Q, Zheng X, Hypoxia accelerates aggressiveness of hepatocellular carcinoma cells involving oxidative stress, epithelial-mesenchymal transition and non-canonical hedgehog signaling, *Cell. Physiol. Biochem* 44 (2018) 1856–1866, 10.1159/000485821.
- [208]. Wang X, Schneider A, HIF-2 α -mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia, *Carcinogenesis* 31 (2010) 1202–1210, 10.1093/carcin/bgq078. [PubMed: 20395290]
- [209]. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, Lee S, Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer, *Proc. Natl. Acad. Sci. USA* 104 (2007) 13092–13097, 10.1073/pnas.0702387104. [PubMed: 17670948]
- [210]. Yang Z, Wang R, Zhang T, Dong X, Hypoxia/lncRNA-AK123072/EGFR pathway induced metastasis and invasion in gastric cancer, *Int. J. Clin. Exp. Med* 8 (2015) 19954–19968. [PubMed: 26884908]
- [211]. Mamo M, Ye IC, Digiacomio JW, Park JY, Downs B, Daniele M, Hypoxia alters the response to anti-EGFR therapy by regulating EGFR expression and downstream signaling in a DNA methylation-specific and HIF-dependent manner, (2020). 10.1158/0008-5472.CAN-20-1232.
- [212]. Wang P, Zhao L, Gong S, Xiong S, Wang J, Zou D, Pan J, Deng Y, Yan Q, Wu N, Liao B, HIF1 α /HIF2 α -Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signalling pathway with positive feedback under hypoxia, *Cell Death Dis.* 12 (2021), 10.1038/s41419-021-03598-8.
- [213]. He C, Sun XP, Qiao H, Jiang X, Wang D, Jin X, Dong X, Wang JJ, Jiang H, Sun X, Downregulating hypoxia-inducible factor-2a improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma, *Cancer Sci.* 103 (2012) 528–534, 10.1111/j.1349-7006.2011.02177.x. [PubMed: 22145922]
- [214]. Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X, Upregulation of HIF-2 α induced by sorafenib contributes to the resistance by activating

- the TGF- α /EGFR pathway in hepatocellular carcinoma cells, *Cell. Signal* 26 (2014) 1030–1039, 10.1016/j.cellsig.2014.01.026. [PubMed: 24486412]
- [215]. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Carolina Gutierrez M, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, 2009. www.pnas.org/cgi/content/full/ .
- [216]. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong STC, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, Mittal V, Gao D, Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance, *Nature* 527 (2015) 472–476, 10.1038/nature15748. [PubMed: 26560033]
- [217]. Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh I-T, De K, Sun L-Z, Doxorubicin in combination with a small TGF β inhibitor: a potential novel therapy for metastatic breast cancer in mouse models, *PLoS One* 5 (2010), e10365, 10.1371/journal.pone.0010365. [PubMed: 20442777]
- [218]. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schmitt SJ, Nikolsky Y, Gelman RS, Polyak K, Molecular definition of breast tumor heterogeneity, *Cancer Cell* 11 (2007) 259–273, 10.1016/j.ccr.2007.01.013. [PubMed: 17349583]
- [219]. Ren J, Chen Y, Song H, Chen L, Wang R, Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line, *J. Cell. Biochem* 114 (2013) 1395–1403. [PubMed: 23255418]
- [220]. Saxena M, Stephens MA, Pathak H, Rangarajan A, Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters, e179–e179, *Cell Death Dis* 2 (2011), 10.1038/cddis.2011.61. [PubMed: 21734725]
- [221]. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB, Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival, *Proc. Natl. Acad. Sci. U. S. A* 107 (2010) 1124–1129, 10.1073/pnas.0909333107. [PubMed: 20080645]
- [222]. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cospers AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, *Sci. Transl. Med* 3 (2011), 10.1126/scitranslmed.3002003.
- [223]. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a Therapeutic target for overcoming egfr inhibitor resistance EMT predicts EGFR and PI3K inhibitor resistance in NSCLC, *Clin. Cancer Res* 19 (2013) 279–290. [PubMed: 23091115]
- [224]. Lu M, Marsters S, Ye X, Luis E, Gonzalez L, Ashkenazi A, E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis, *Mol. Cell* 54 (2014) 987–998, 10.1016/j.molcel.2014.04.029. [PubMed: 24882208]
- [225]. Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Nieto MA, Snail blocks the cell cycle and confers resistance to cell death, *Genes Dev.* 18 (2004) 1131–1143, 10.1101/gad.294104. [PubMed: 15155580]
- [226]. Ni T, Li X-Y, Lu N, An T, Liu Z-P, Fu R, Lv W-C, Zhang Y-W, Xu X-J, Grant Rowe R, Lin Y-S, Scherer A, Feinberg T, Zheng X-Q, Chen B-A, Liu XS, Guo Q-L, Wu Z-Q, Weiss SJ, Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer, *Nat. Cell Biol* 18 (2016) 1221–1232, 10.1038/ncb3425. [PubMed: 27749822]
- [227]. Wu W-S, Heinrichs S, Xu D, Garrison SP, Zambetti GP, Adams JM, Look AT, Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma, *Cell* 123 (2005) 641–653, 10.1016/j.cell.2005.09.029. [PubMed: 16286009]

- [228]. Wu D-W, Lee M-C, Hsu N-Y, Wu T-C, Wu J-Y, Wang Y-C, Cheng Y-W, Chen CY, Lee H, FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF- κ B/Slug-mediated PUMA reduction, *Oncogene* 34 (2015) 2505–2515, 10.1038/onc.2014.184. [PubMed: 24998847]
- [229]. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF, Therapeutic implications of cancer stem cells, *Curr. Opin. Genet. Dev* 14 (2004) 43–47, 10.1016/j.gde.2003.11.007. [PubMed: 15108804]
- [230]. Lou Y, Diao L, Cuentas ERP, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL, Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma, *Clin. Cancer Res* 22 (2016) 3630–3642, 10.1158/1078-0432.CCR-15-1434. [PubMed: 26851185]
- [231]. Mahmoudian RA, Mozhgani S, Abbaszadegan MR, Mokhlessi L, Montazer M, Gholamin M, Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC, *J. Mol. Histol* 52 (2021) 597–609, 10.1007/s10735-021-09971-3. [PubMed: 33884540]
- [232]. Koliijn K, Verhoef EI, Smid M, Bottcher R, Jenster GW, Debets R, Van Leenders GJLH, Epithelial–mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression, *Cancer Res.* 78 (2018) 4671–4679, 10.1158/0008-5472.CAN-17-3752. [PubMed: 29921693]
- [233]. Hu Z, Cunnea P, Zhong Z, Lu H, Osagie OI, Campo L, Artibani M, Nixon K, Ploski J, Gonzalez LS, Alsaadi A, Wietek N, Damato S, Dhar S, Blagden SP, Yau C, Hester J, Albukhari A, Aboagye EO, Fotopoulou C, Ahmed A, The oxford classic links epithelial-to-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers, *Clin. Cancer Res* 27 (2021) 1570–1579, 10.1158/1078-0432.CCR-20-2782. [PubMed: 33446563]
- [234]. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, BerentMaoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS, Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma, *Cell* 165 (2016) 35–44, 10.1016/j.cell.2016.02.065. [PubMed: 26997480]
- [235]. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y, Cancer metastasis is accelerated through immunosuppression during snail-induced EMT of cancer cells, *Cancer Cell* 15 (2009) 195–206, 10.1016/j.ccr.2009.01.023. [PubMed: 19249678]
- [236]. Akalay I, Janji B, Hasmim M, Noman MZ, And e F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, Sabbah M, Tan TZ, Keira JH, Hung NTY, Thiery JP, Mami-Chouaib F, Chouaib S, Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from t-cell-mediated lysis, *Cancer Res.* 73 (2013) 2418–2427, 10.1158/0008-5472.CAN-12-2432. [PubMed: 23436798]
- [237]. Qian Y, Yao W, Yang T, Yang Y, Liu Y, Shen Q, Zhang J, Qi W, Wang J, aPKC- ν P-Sp1/Snail signaling induces epithelial–mesenchymal transition and immunosuppression in cholangiocarcinoma, *Hepatology* 66 (2017) 1165–1182, 10.1002/hep.29296. [PubMed: 28574228]
- [238]. Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura E, Sugiyama A, Mandai M, Konishi I, Matsumura N, Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation, *Nat. Commun* 9 (2018) 1–12, 10.1038/s41467-018-03966-7. [PubMed: 29317637]
- [239]. Xiao M, Hasmim M, Lequeux A, Van Moer K, Tan TZ, Gilles C, Hollier BG, Thiery JP, Berchem G, Janji B, Noman MZ, Epithelial to mesenchymal transition regulates surface pd-11 via cmtm6 and cmtm7 induction in breast cancer, *Cancers* 13 (2021) 1–12, 10.3390/cancers13051165.
- [240]. Takimoto CH, Chao MP, Gibbs C, McCamish MA, Liu J, Chen JY, Majeti R, Weissman IL, The Macrophage “Do not eat me” signal, CD47, is a clinically validated cancer immunotherapy target, *Ann. Oncol* 30 (2019) 486–489, 10.1093/annonc/mdz006. [PubMed: 30689700]
- [241]. Noman MZ, Van Moer K, Marani V, Gemmill RM, Tranchevent LC, Azuaje F, Muller A, Chouaib S, Thiery JP, Berchem G, Janji B, CD47 is a direct target of SNAIL1 and ZEB1 and its

- blockade activates the phagocytosis of breast cancer cells undergoing EMT, *OncoImmunology* 7 (2018), 10.1080/s2162402X.2017.1345415.
- [242]. Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA, Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas, *Cancer Res.* 77 (2017) 3982–3989, 10.1158/0008-5472.CAN-16-3292. [PubMed: 28428275]
- [243]. Dongre A, Rashidian M, Eaton EN, Reinhardt F, Thiru P, Zagorulya M, Nepal S, Banaz T, Martner A, Spranger S, Weinberg RA, Direct and indirect regulators of epithelial–mesenchymal transition– mediated immunosuppression in breast carcinomas, *Cancer Discov.* 11 (2021) 1286–1305, 10.1158/2159-8290.CD-20-0603. [PubMed: 33328216]
- [244]. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, Peng D, Antonia S, Mediavilla-Varela M, Robertson G, Jones S, Suraokar M, Welsh JW, Erez B, Wistuba II, Chen L, Peng D, Wang S, Ullrich SE, Heymach JV, Kurie JM, Qin FFX, Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression, *Nat. Commun* 5 (2014), 10.1038/ncomms6241.
- [245]. Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, Tan TZ, Mami-Chouaib F, Thiery JP, Chouaib S, The immune checkpoint ligand PD-11 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200, *OncoImmunology* 6 (2017) 1–7, 10.1080/2162402X.2016.1263412.
- [246]. Guo Y, Lu X, Chen Y, Rendon B, Mitchell RA, Cuatrecasas M, Cortés M, Postigo A, Liu Y, Dean DC, Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells, *Sci. Adv* 7 (2021), 10.1126/sciadv.abd7455.
- [247]. Tijink BM, Buter J, De Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, Van Dongen GA, A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus, *Clin. Cancer Res* 12 (2006) 6064–6072. [PubMed: 17062682]
- [248]. Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, Erhardt T, Gronau S, Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma, *Oral. Oncol* 44 (2008) 823–829. [PubMed: 18203652]
- [249]. Perez A, Neskey DM, Wen J, Goodwin JW, Slingerland J, Pereira L, Weigand S, Franzmann EJ, Targeting CD44 in head and neck squamous cell carcinoma (HNSCC) with a new humanized antibody RO5429083, *Cancer Res.* 72 (2012), 2521–2521.
- [250]. Wang C, Wang Z, Chen C, Fu X, Wang J, Fei X, Yan X, Xu R, A low MW inhibitor of CD44 dimerization for the treatment of glioblastoma, *Br. J. Pharmacol* 177 (2020) 3009–3023. [PubMed: 32080830]
- [251]. Aguilera KY, Huang H, Du W, Hagopian MM, Wang Z, Hinz S, Hwang TH, Wang H, Fleming JB, Castrillon DH, Ren X, Ding K, Brekken RA, Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma, *Mol. Cancer Ther* 16 (2017) 2473–2485, 10.1158/1535-7163.MCT-16-0834. [PubMed: 28864681]
- [252]. Grither WR, Longmore GD, Inhibition of tumor–microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain, *Proc. Natl. Acad. Sci. U. S. A* 115 (2018), 10.1073/pnas.1805020115.
- [253]. Jin H, Ham I-H, Oh HJ, Bae CA, Lee D, Kim Y-B, Son S-Y, Chwae Y-J, Han SU, Brekken RA, Hur H, Inhibition of discoidin domain receptor 1 prevents stroma-induced peritoneal metastasis in gastric carcinoma, *Mol. Cancer Res* 16 (2018) 1590–1600, 10.1158/1541-7786.MCR-17-0710. [PubMed: 29866925]
- [254]. Berestjuk I, Lecacheur M, Carminati A, Diazzi S, Rovera C, Prod'homme V, Ohanna M, Popovic A, Mallavialle A, Larbret F, Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanoma, *EMBO Mol. Med* 14 (2022), e11814.
- [255]. Kothiwale S, Borza CM, Lowe EW Jr, Pozzi A, Meiler J, Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery, *Drug Discov. Today* 20 (2015) 255–261. [PubMed: 25284748]
- [256]. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP, Phase I study of GC1008 (fresolimumab): a human anti-transforming growth

- factor-beta (TGF β) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma, *PLoS One* 9 (2014), e90353. [PubMed: 24618589]
- [257]. Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, Nakerakanti S, York M, Farina G, Whitfield ML, Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients, *J. Clin. Investig* 125 (2015) 2795–2807. [PubMed: 26098215]
- [258]. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors, *Proc. Natl. Acad. Sci* 108 (2011) 2909–2914. [PubMed: 21282607]
- [259]. Vallet SD, Ricard-Blum S, Lysyl oxidases: from enzyme activity to extracellular matrix cross-links, *Essays Biochem.* 63 (2019) 349–364. [PubMed: 31488698]
- [260]. Benson III AB, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, Kudrik F, A phase II randomized, double-blind, placebo-controlled study of simtuzumab or placebo in combination with gemcitabine for the first-line treatment of pancreatic adenocarcinoma, *Oncologist* 22 (2017) 241, e15. [PubMed: 28246206]
- [261]. Peng T, Lin S, Meng Y, Gao P, Wu P, Zhi W, Ding W, Cao C, Wu P, LOXL2 small molecule inhibitor restrains malignant transformation of cervical cancer cells by repressing LOXL2 -induced epithelial-mesenchymal transition (EMT), *Cell Cycle* (2022) 1–15, 10.1080/15384101.2022.2073047.
- [262]. Tang H, Leung L, Saturno G, Viros A, Smith D, Di Leva G, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R, Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface, *Nat. Commun* 8 (2017) 14909, 10.1038/ncomms14909. [PubMed: 28416796]
- [263]. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittmer SM, Nippgen J, Picard M, Nabors LB, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycineaspartic acid peptide, in recurrent glioblastoma multiforme, *JCO* 26 (2008) 5610–5617, 10.1200/JCO.2008.16.7510.
- [264]. Javadi S, Rostamizadeh K, Hejazi J, Parsa M, Fathi M, Curcumin mediated down-regulation of α V β 3 integrin and up-regulation of pyruvate dehydrogenase kinase 4 (PDK4) in Erlotinib resistant SW480 colon cancer cells, *Phytother. Res* 32 (2018) 355–364. [PubMed: 29168312]
- [265]. Capelletto E, Bironzo P, Denis L, Koustenis A, Bungaro M, Novello S, Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial, *Future Oncol.* 18 (2022) 1907–1915. [PubMed: 35285277]
- [266]. Wang-Gillam A, Lockhart AC, Tan BR, Suresh R, Lim K-H, Ratner L, DeNardo DG, Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer., *American Society of Clinical Oncology*, 2018.
- [267]. Dawson JC, Serrels B, Byron A, Muir MT, Makda A, García-Muñoz A, von Kriegsheim A, Lietha D, Carragher NO, Frame MC, A synergistic anticancer FAK and HDAC inhibitor combination discovered by a novel chemical–genetic high-content phenotypic screenantitumor effects of FAK and HDAC inhibitors, *Mol. Cancer Ther* 19 (2020) 637–649. [PubMed: 31784455]
- [268]. Wu L, Wang J, Wang L, Lu W, Wang K, Lin A, Li N, Li L, Su N, Xie S, A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer., *American Society of Clinical Oncology*, 2022.
- [269]. Mak G, Soria J-C, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours, *Br. J. Cancer* 120 (2019) 975–981. [PubMed: 30992546]
- [270]. Soria J-C, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TRJ, Zalzman G, Bahleda R, Hollebecque A, A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors, *Ann. Oncol* 27 (2016) 2268–2274. [PubMed: 27733373]
- [271]. de Jonge MJ, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DA, Abdul Razak AR, De Vos FY, Verheijen RB, Schnell D, Phase I study of BI 853520, an inhibitor of focal

- adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies, *Target. Oncol* 14 (2019) 43–55. [PubMed: 30756308]
- [272]. Dolor A, Szoka FC, Digesting a path forward: the utility of collagenase tumor treatment for improved drug delivery, *Mol. Pharm* 15 (2018) 2069–2083, 10.1021/acs.molpharmaceut.8b00319. [PubMed: 29767984]
- [273]. Ng MR, Brugge JS, A stiff blow from the stroma: collagen crosslinking drives tumor progression, *Cancer Cell* 16 (2009) 455–457, 10.1016/j.ccr.2009.11.013. [PubMed: 19962663]
- [274]. Leung L, Niculescu-Duvaz D, Smithen D, Lopes F, Callens C, McLeary R, Saturno G, Davies L, Aljarah M, Brown M, Johnson L, Zambon A, Chambers T, Ménard D, Bayliss N, Knight R, Fish L, Lawrence R, Challinor M, Tang H, Marais R, Springer C, Anti-metastatic inhibitors of lysyl oxidase (LOX): design and structure-activity relationships, *J. Med. Chem* 62 (2019) 5863–5884, 10.1021/acs.jmedchem.9b00335. [PubMed: 31070916]
- [275]. von Mässenhausen A, Sanders C, Brägelmann J, Konantz M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schrock A, Bootz F, Brossart P, Kirfel J, Lengerke C, Perner S, Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib: DDR2 inhibition with dasatinib in HNSCC, *Int. J. Cancer* 139 (2016) 2359–2369, 10.1002/ijc.30279. [PubMed: 27434411]
- [276]. Li L, Hao X, Qin J, Tang W, He F, Smith A, Zhang M, Simeone DM, Qiao XT, Chen Z-N, Lawrence TS, Xu L, Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice, *e12, Gastroenterology* 146 (2014) 1108–1118, 10.1053/j.gastro.2013.12.035. [PubMed: 24397969]
- [277]. Zheng J, Zhao S, Yu X, Huang S, Liu HY, Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth, *Theranostics* 7 (2017) 1373–1388, 10.7150/thno.17826. [PubMed: 28435472]
- [278]. Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S, A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma, *Neuro Oncol.* 17 (2015) 1386–1392, 10.1093/neuonc/nov085. [PubMed: 26008604]
- [279]. Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalil M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Gy rffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD, FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy, *ELife* 8 (2019), e47327, 10.7554/eLife.47327. [PubMed: 31478830]
- [280]. Falandry C, Rousseau F, Mouret-Reynier M-A, Tinquaut F, Lorusso D, Herrstedt J, Savoye A-M, Stefani L, Bourbouloux E, Sverdlin R, D’Hondt V, Lortholary A, Brachet P-E, Zannetti A, Malaurie E, Venat-Bouvet L, T edan O, Mourey L, Pujade-Lauraine E, Freyer G, Groupe d’investigateurs nationaux pour l’Étude des Cancers de l’Ovaire et du sein (GINECO), efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO/GCIG randomized clinical trial, *JAMA Oncol.* 7 (2021) 853, 10.1001/jamaoncol.2021.0696. [PubMed: 33885718]
- [281]. Machida H, Tokunaga H, Matsuo K, Matsumura N, Kobayashi Y, Tabata T, Kaneuchi M, Nagase S, Mikami M, Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: a systematic review and meta-analysis, *Eur. J. Surg. Oncol* 46 (2020) 868–875, 10.1016/j.ejso.2019.11.520. [PubMed: 31818526]
- [282]. Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, Nakagawa K, A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors, *Cancer Chemother. Pharm* 77 (2016) 997–1003, 10.1007/s00280-016-3010-1.
- [283]. Almasabi S, Ahmed AU, Boyd R, Williams BRG, A potential role for integrin-linked kinase in colorectal cancer growth and progression via regulating senescence and immunity, *Front. Genet* 12 (2021), 10.3389/fgene.2021.638558.
- [284]. Nguyen MLT, Bui KC, Scholta T, Xing J, Bhuria V, Sipos B, Wilkens L, Nguyen Linh T, Velavan TP, Bozko P, Plentz RR, Targeting interleukin 6 signaling by monoclonal antibody

- siltuximab on cholangiocarcinoma, *J. Gastroenterol. Hepatol. (Aust.)* 36 (2021) 1334–1345, 10.1111/jgh.15307.
- [285]. Al-Jomah N, Al-Mohanna FH, Aboussekhra A, Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3/AUF1 pathway, *Carcinogenesis* 42 (2021) 1439–1448, 10.1093/carcin/bgab102. [PubMed: 34718441]
- [286]. Guan J, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, Zhang T, Jia C, Lu Z, Chen J, Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells, *Cancer Lett.* 345 (2014) 132–139, 10.1016/j.canlet.2013.12.006. [PubMed: 24334138]
- [287]. Moatassim-Billah S, Duluc C, Samain R, Jean C, Perraud A, Decaup E, Cassant-Sourdy S, Bakri Y, Selves J, Schmid H, Martineau Y, Mathonnet M, Pyronnet S, Bousquet C, Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts, *Oncotarget* 7 (2016) 41584–41598, 10.18632/oncotarget.9296. [PubMed: 27177087]
- [288]. Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y, Shimada M, Nabpaclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro, *Cancer Sci.* 109 (2018) 2509–2519, 10.1111/cas.13694. [PubMed: 29902349]
- [289]. Al-Harbi B, Aboussekhra A, Cucurbitacin I (JSI-124)-dependent inhibition of STAT3 permanently suppresses the pro-carcinogenic effects of active breast cancer-associated fibroblasts, *Mol. Carcinog* 60 (2021) 242–251, 10.1002/mc.23287. [PubMed: 33621387]
- [290]. Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiock S, Haura EB, Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer, *J. Thorac. Oncol* 9 (2014) 974–982, 10.1097/JTO.000000000000193. [PubMed: 24922005]
- [291]. Rossi JF, Egrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B, A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer, *Br. J. Cancer* 103 (2010) 1154–1162, 10.1038/sj.bjc.6605872. [PubMed: 20808314]
- [292]. Bae CA, Ham IH, Oh HJ, Lee D, Woo J, Son SY, Yoon JH, Lorens JB, Brekken RA, Kim TM, Han SU, Park WS, Hur H, Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma, *Gastric Cancer* 23 (2020) 824–836, 10.1007/s10120-020-01066-4. [PubMed: 32239298]
- [293]. Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, Park JO, Ramirez RA, Abad DG, Feliu J, Muñoz A, Ponz-Sarvisé M, Peled A, Lustig TM, Bohana-Kashtan O, Shaw SM, Sorani E, Chaney M, Kadosh S, Vainstein Haras A, Von Hoff DD, Hidalgo M, BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial, *Nat. Med* 26 (2020) 878–885, 10.1038/s41591-020-0880-x. [PubMed: 32451495]
- [294]. Ren Y, huan Jia H, qi Xu Y, Zhou X, hui Zhao X, fei Wang Y, Song X, yan Zhu Z, Sun T, Dou Y, ping Tian W, lan Zhao X, sheng Kang C, Mei M, Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-β1 secretion, *Mol. Cancer* 17 (2018) 1–14, 10.1186/s12943-018-0758-4. [PubMed: 29304823]
- [295]. Otvos L, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E, Design and development of a peptide-based adiponectin receptor agonist for cancer treatment, *BMC Biotechnol.* 11 (2011) 90, 10.1186/1472-6750-11-90. [PubMed: 21974986]
- [296]. Philp LK, Rockstroh A, Lehman M, Sadowski MC, Bartonicek N, Wade JD, Otvos L, Nelson CC, Adiponectin receptor activation inhibits prostate cancer xenograft growth, *Endocr. -Relat. Cancer* 27 (2020) 711–729, 10.1530/ERC-20-0297. [PubMed: 33112829]
- [297]. Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, Lynch MP, Rueda BR, Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2), *J. Biol. Chem* 281 (2006) 26320–26328, 10.1074/jbc.M601991200. [PubMed: 16825198]

- [298]. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML, Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer, *Breast Cancer Res.* 11 (2009) 1–12, 10.1186/BCR2321/COMMENTS.
- [299]. Gyamfi J, Lee YH, Min BS, Choi J, Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis, *Sci. Rep* 9 (2019), 10.1038/s41598-019-47707-2.
- [300]. Su F, Ahn S, Saha A, DiGiovanni J, Kolonin MG, Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance, *Oncogene* 38 (2019) 1979–1988, 10.1038/s41388-018-0558-8. [PubMed: 30361686]
- [301]. Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, Broz ML, Mori H, Wu D, Adoumie M, Del Rosario R, Li O, Buchmann T, Liang B, Malato J, Arce Vargus F, Sheppard D, Hann BC, Mirza A, Quezada SA, Rosenblum MD, Krummel MF, Balmain A, Akhurst RJ, α -PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α -TGF β antibody to promote durable rejection and immunity in squamous cell carcinomas *11 Medical and Health Sciences 1107 Immunology 11 Medical and Health Sc, J. Immunother. Cancer* 7 (2019) 1–15, 10.1186/s40425-018-0493-9. [PubMed: 30612589]
- [302]. Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, Winter C, Malkova N, Sun F, Jaworski J, Best A, Pao L, Hebert A, Levit M, Protopopov A, Pollard J, Bahjat K, Wiederschain D, Sharma S, Pan-TGF β inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade, *OncoImmunology* 9 (2020), 10.1080/2162402X.2020.1811605.
- [303]. David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C, A novel bifunctional anti-PD-L1/TGF- β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells, *OncoImmunology* 6 (2017), 10.1080/2162402X.2017.1349589.
- [304]. Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR, M7824, a novel bifunctional anti-PD-L1/TGF β Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine, *OncoImmunology* 7 (2018) 1–14, 10.1080/2162402X.2018.1426519.
- [305]. Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernández VM, Jenkins MH, Fontana RE, Deshpande A, Locke G, Sabzevari H, Radvanyi L, Lo KM, Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-, *Sci. Transl. Med* 10 (2018), 10.1126/scitranslmed.aan5488.
- [306]. Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JL, Palena C, Schlom J, Dual targeting of TGF- β and PD-L1 via a bifunctional anti-PD-L1/TGF- β R2 agent: Status of preclinical and clinical advances, *J. Immunother. Cancer* 8 (2020) 1–10, 10.1136/jitc-2019-000433.
- [307]. Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marte JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL, Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF β , in advanced solid tumors, *Clin. Cancer Res* 24 (2018) 1287–1295, 10.1158/1078-0432.CCR-17-2653. [PubMed: 29298798]
- [308]. Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, Luo S, Zhou P, Wu K, The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF- β and PD-L1, *J. Hematol. Oncol* 14 (2021) 1–22, 10.1186/s13045-021-01045-x. [PubMed: 33402199]
- [309]. Peng DH, Rodriguez BL, Diao L, Gaudreau PO, Padhye A, Konen JM, Ochieng JK, Class CA, Fradette JJ, Gibson L, Chen L, Wang J, Byers LA, Gibbons DL, Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers, *Nat. Commun* 12 (2021) 1–15, 10.1038/s41467-021-22875-w. [PubMed: 33397941]
- [310]. Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H, Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma, *Gut* 66 (2017) 157–167, 10.1136/gutjnl-2015-310514. [PubMed: 26452628]
- [311]. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW,

- Sutton JC, Holland EC, Daniel D, Joyce JA, CSF-1R inhibition alters macrophage polarization and blocks glioma progression, *Nat. Med* 19 (2013) 1264–1272, 10.1038/nm.3337. [PubMed: 24056773]
- [312]. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, WangGillam A, Goedegebuure SP, Linehan DC, De Nardo DG, CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models, *Cancer Res.* 74 (2014) 5057–5069, 10.1158/0008-5472.CAN-13-3723. [PubMed: 25082815]
- [313]. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klamann I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, deVisser KE, Italiano A, LeTourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy, *Cancer Cell* 25 (2014) 846–859, 10.1016/j.ccr.2014.05.016. [PubMed: 24898549]
- [314]. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans, *Science* 331 (2011) 1612–1616. [PubMed: 21436454]
- [315]. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, Schmid MC, Pink M, Winkler DG, Rausch M, Palombella VJ, Kutok J, McGovern K, Frazer KA, Wu X, Karin M, Sasik R, Cohen EEW, Varner JA, PI3K γ 3 is a molecular switch that controls immune suppression, *Nature* 539 (2016) 437–442, 10.1038/nature19834. [PubMed: 27642729]
- [316]. Ravi J, Elbaz M, Wani NA, Nasser MW, Ganju RK, Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway, *Mol. Carcinog* 55 (2016) 2063–2076, 10.1002/mc.22451. [PubMed: 26741322]
- [317]. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM, Gemcitabine selectively eliminates splenic Gr-1⁺/CD11b⁺ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, *Clin. Cancer Res* 11 (2005) 6713–6721, 10.1158/1078-0432.CCR-05-0883. [PubMed: 16166452]
- [318]. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, ebe C, Ghiringhelli F, 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, *Cancer Res.* 70 (2010) 3052–3061, 10.1158/0008-5472.CAN-09-3690. [PubMed: 20388795]
- [319]. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH, Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients, *Clin. Cancer Res* 15 (2009) 2148–2157, 10.1158/1078-0432.CCR-08-1332. [PubMed: 19276286]
- [320]. Sevko A, Michels T, Vrohling M, Umansky L, Beckhove P, Kato M, Shurin GV, Shurin MR, Umansky V, Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model, *J. Immunol* 190 (2013) 2464–2471, 10.4049/jimmunol.1202781. [PubMed: 23359505]
- [321]. Qin H, Lerman B, Sakamaki I, Wei G, Cha SC, Rao SS, Qian J, Hailemichael Y, Nurieva R, Dwyer KC, Roth J, Yi Q, Overwijk WW, Kwak LW, Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice, *Nat. Med* 20 (2014) 676–681, 10.1038/nm.3560. [PubMed: 24859530]
- [322]. Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD, Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors, *EBioMedicine* 6 (2016) 50–58, 10.1016/j.ebiom.2016.02.024. [PubMed: 27211548]
- [323]. Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze TJ, Razon H, Hawila E, Wildbaum G, Utikal J, Karin N, Umansky V, CCR5⁺ myeloid-derived suppressor cells are enriched and activated in melanoma lesions, *Cancer Res.* 78 (2018) 157–167, 10.1158/0008-5472.CAN-17-0348. [PubMed: 29089297]

- [324]. Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT, Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy, *JCI Insight* 4 (2019) 1–12, 10.1172/jci.insight.126853.
- [325]. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I, Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function, *J. Exp. Med* 203 (2006) 2691–2702, 10.1084/jem.20061104. [PubMed: 17101732]
- [326]. Veltman JD, Lambers ME, Van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans P, COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function, *BMC Cancer* 10 (2010) 1–13. [PubMed: 20047689]
- [327]. Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI, Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer, *Clin. Cancer Res* 16 (2010) 1812–1823, 10.1158/1078-0432.CCR-09-3272. [PubMed: 20215551]
- [328]. Cheng P, Kumar V, Liu H, Youn JI, Fishman M, Sherman S, Gabrilovich D, Effects of notch signaling on regulation of myeloid cell differentiation in cancer, *Cancer Res.* 74 (2014) 141–152, 10.1158/0008-5472.CAN-13-1686. [PubMed: 24220241]
- [329]. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI, All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients, *Cancer Res.* 66 (2006) 9299–9307, 10.1158/0008-5472.CAN-06-1690. [PubMed: 16982775]
- [330]. Cui E, Guo H, Shen M, Yu H, Gu D, Mao W, Wang X, Adiponectin inhibits migration and invasion by reversing epithelial-mesenchymal transition in non-small cell lung carcinoma, *Oncol. Rep* 40 (2018) 1330–1338, 10.3892/or.2018.6523. [PubMed: 29956809]
- [331]. Cui R, Yue W, Lattime EC, Stein MN, Xu Q, Tan XL, Targeting tumor-associated macrophages to combat pancreatic cancer, *Oncotarget* 7 (2016) 50735–50754, 10.18632/oncotarget.9383. [PubMed: 27191744]
- [332]. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR, “Re-educating” tumor-associated macrophages by targeting NF- κ B, *J. Exp. Med* 205 (2008) 1261–1268, 10.1084/jem.20080108. [PubMed: 18490490]
- [333]. Law AMK, Valdes-mora F, Gallego-ortega D, Myeloid-derived suppressor cells as a therapeutic, *Cells* 27 (2020) 561.
- [334]. Tang H, Li H, Sun Z, Targeting myeloid-derived suppressor cells for cancer therapy, *Cancer Biol. Med* 18 (2021) 992–1009, 10.20892/j.issn.2095-3941.2020.0806. [PubMed: 34403220]
- [335]. Song JH, Eum DY, Park SY, Jin YH, Shim JW, Park SJ, Kim MY, Park SJ, Heo K, Choi YJ, Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells, *PLoS ONE* 15 (2020) 1–15, 10.1371/journal.pone.0240533.
- [336]. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G, Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1 α , *Mol. Cancer Ther* 3 (2004) 233–244. [PubMed: 15026543]
- [337]. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G, Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 α , *Mol. Cancer Ther* 7 (2008) 90–100, 10.1158/1535-7163.MCT-07-0463. [PubMed: 18202012]
- [338]. Zhang H, Wong CCL, Wei H, Gilkes DM, Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B, Winnard PT, Raman V, Zhen L, Mitzner WA, Sukumar S, Semenza GL, HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs, *Oncogene* 31 (2012) 1757–1770, 10.1038/onc.2011.365. [PubMed: 21860410]
- [339]. Zhang H, Qian DZ, Tan YS, Lee KA, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL, Digoxin and other cardiac glycosides inhibit HIF-1 α

- synthesis and block tumor growth, *Proc. Natl. Acad. Sci. USA* 105 (2008) 19579–19586, 10.1073/pnas.0809763105. [PubMed: 19020076]
- [340]. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgu AJ, Doroshow JH, Melillo G, Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1 α in advanced solid tumors, *Clin. Cancer Res* 17 (2011) 5123–5131, 10.1158/1078-0432.CCR-11-0682. [PubMed: 21673063]
- [341]. Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, Molina-Cerrillo J, Grande E, Targeting HIF-2 α in clear cell renal cell carcinoma: a promising therapeutic strategy, *Crit. Rev. Oncol. / Hematol* 111 (2017) 117–123, 10.1016/j.critrevonc.2017.01.013. [PubMed: 28259286]
- [342]. Lee KA, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL, Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization, *Proc. Natl. Acad. Sci. USA* 106 (2009) 17910–17915, 10.1073/pnas.0909353106. [PubMed: 19805192]
- [343]. Mabeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P, 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF, *Cancer Cell* 3 (2003) 363–375, 10.1016/S1535-6108(03)00077-1. [PubMed: 12726862]
- [344]. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, Fisher RJ, Shoemaker RH, Melillo G, Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity, *Cancer Res.* 65 (2005) 9047–9055, 10.1158/0008-5472.CAN-05-1235. [PubMed: 16204079]
- [345]. Nickols NG, Jacobs CS, Farkas ME, Dervan PB, Modulating hypoxia-inducible transcription by disrupting the HIF-1–DNA interface, *2* (2007) 561–571.
- [346]. Bailey CM, Liu Y, Peng G, Zhang H, He M, Sun D, Zheng P, Liu Y, Wang Y, Liposomal formulation of HIF-1 α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer, *Nanomed.: Nanotechnol. Biol. Med* 29 (2020), 102278, 10.1016/j.nano.2020.102278.
- [347]. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM, Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway, *Cancer Cell* 6 (2004) 33–43, 10.1016/j.ccr.2004.06.009. [PubMed: 15261140]
- [348]. Shin DH, Chun YS, Lee DS, Huang LE, Park JW, Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1, *Blood* 111 (2008) 3131–3136, 10.1182/blood-2007-11-120576. [PubMed: 18174379]
- [349]. Shan HL, Dong HS, Chun YS, Myung KL, Kim MS, Park JW, A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1 α , *Mol. Cancer Ther* 7 (2008) 3729–3738, 10.1158/1535-7163.MCT-08-0074. [PubMed: 19074848]
- [350]. Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS, Treatment with hif-1 α antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice, *J. Thorac. Oncol* 5 (2010) 940–949, 10.1097/JTO.0b013e3181dc211f. [PubMed: 20512076]
- [351]. Tang W, Zhao G, Small molecules targeting HIF-1 α pathway for cancer therapy in recent years, *Bioorg. Med. Chem* 28 (2020), 115235, 10.1016/j.bmc.2019.115235. [PubMed: 31843464]
- [352]. Wong CCL, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME, Semenza GL, Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis, *J. Mol. Med* 90 (2012) 803–815, 10.1007/s00109-011-0855-y. [PubMed: 22231744]
- [353]. Liu H, Chen C, Zeng J, Zhao Z, Hu Q, MicroRNA-210–3p is transcriptionally upregulated by hypoxia induction and thus promoting EMT and chemoresistance in glioma cells, *PLoS ONE* 16 (2021) 1–16, 10.1371/journal.pone.0253522.
- [354]. Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, Park JW, Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading, *Cancer Lett.* 255 (2007) 107–116, 10.1016/j.canlet.2007.03.026. [PubMed: 17502124]

- [355]. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T, Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer, *Cancer Res.* 67 (2007) 4157–4163, 10.1158/0008-5472.CAN-06-2355. [PubMed: 17483326]
- [356]. Lin J, Zhan T, Duffy D, Hoffman-censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Ph D, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci MA, Kelly WK, A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA, *Am. J. Cancer Ther. Pharm* 2 (2014) 21–32.
- [357]. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF, Albæk C, Schröder H, Ørum H, A RNA antagonist of hypoxiainducible factor-1 α , EZN-2968, inhibits tumor cell growth, *Mol. Cancer Ther* 7 (2008) 3598–3608, 10.1158/1535-7163.MCT-08-0510. [PubMed: 18974394]
- [358]. Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummur S, Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1 α), in patients with refractory solid tumors, *Cancer Chemother. Pharmacol* 73 (2014) 343–348, 10.1007/s00280-013-2362-z. [PubMed: 24292632]
- [359]. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G, Schedule-dependent inhibition of hypoxia-inducible factor-1 α protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts, *Cancer Res.* 64 (2004) 6845–6848, 10.1158/0008-5472.CAN-04-2116. [PubMed: 15466170]
- [360]. Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, Carvo I, Signoretti S, Bruick RK, Josey JA, Wallace EM, Kaelin WG, On-target efficacy of a HIF-2 α antagonist in preclinical kidney cancer models, *Nature* 539 (2016) 107–111, 10.1038/nature19795. [PubMed: 27595393]
- [361]. Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie XJ, Kapur P, McKay RM, Brugarolas J, Targeting renal cell carcinoma with a HIF-2 antagonist, *Nature* 539 (2016) 112–117, 10.1038/nature19796. [PubMed: 27595394]
- [362]. Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS, Grina JA, Halfmann MM, Maddie MA, Olive SR, Schlachter ST, Tan H, Wang B, Wang K, Xie S, Xu R, Yang H, Josey JA, A small-molecule antagonist of HIF2 α is efficacious in preclinical models of renal cell carcinoma, *Cancer Res.* 76 (2016) 5491–5500, 10.1158/0008-5472.CAN-16-0473. [PubMed: 27635045]
- [363]. Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK, Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2 α antagonist in patients with previously treated advanced clear cell renal cell carcinoma, *J. Clin. Oncol* 36 (2018) 867–874, 10.1200/JCO.2017.74.2627. [PubMed: 29257710]
- [364]. Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, Wehn PM, Yang H, Dixon DD, Czerwinski RM, Du X, Ged EL, Han G, Tan H, Wong T, Xie S, Josey JA, Wallace EM, 3-[(1 S,2 S,3 R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible Factor 2 α (HIF-2 α)inhibitor for the treatment of clear cell renal cell carcinoma, *J. Med. Chem* 62 (2019) 6876–6893, 10.1021/acs.jmedchem.9b00719. [PubMed: 31282155]
- [365]. Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E, Inhibition of hypoxia-inducible factor-2 α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis, *Nat. Med* 27 (2021) 802–805, 10.1038/s41591-021-01324-7. [PubMed: 33888901]
- [366]. Yu Y, Yu Q, Zhang X, Allosteric inhibition of HIF-2 α as a novel therapy for clear cell renal cell carcinoma, *Drug Discov. Today* 24 (2019) 2332–2340, 10.1016/j.drudis.2019.09.008. [PubMed: 31541711]

- [367]. Deeks ED, Belzutifan: first approval, *Drugs* 81 (2021) 1921–1927, 10.1007/s40265-021-01606-x. [PubMed: 34613603]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





Fig. 1.

A summary of various extracellular matrix signals implicated in EMT regulation in the tumor microenvironment. Various ECM molecules, ECM remodeling proteins and physical forces exerted from ECM in the tumor microenvironment activate various biochemical and mechanical signaling pathways to regulate the EMT inducers and EMT transcription factors to drive EMT and tumor progression.

**Fig. 2.**

A summary of various secreted factors implicated in EMT induction by stromal cells and immune cells. CAFs, CAAs and immune cells including T lymphocytes, TAMs and MDSCs could promote EMT in cancer cells through the secretion of cytokines, chemokines and growth factors, such as TGFβ, IL-6, CXCL12, CCL18, FGF and HGF. Meanwhile, cancer cells secrete various factors to stimulate CAFs or CAAs formation and recruit more Tregs, TAMs or MDSCs. CAFs: cancer associated fibroblasts; CAAs: cancer associated adipocytes; TAMs: tumor associated macrophages; MDSCs: myeloid-derived suppressor cells.




Fig. 3. A schematic diagram summarizing mechanisms underlying hypoxia-mediated EMT. Hypoxia activates EMT by directly increasing EMT-TFs expression or stimulating various signaling pathways, including TGFβ, Notch, Hedgehog pathway and EGFR pathway. Direct transcription targets, like SNAI1, TGFβ, NOTCH1–1, SHH and EGFR are listed in diagram. Except for HIF-1/2α, ROS could also stimulate EMT by promoting SNAI1 nuclear translocation under hypoxia condition.

Table 1

Targeting extracellular matrix.

Drug/inhibitor	Target	Effectiveness	Reference
Bivatuzumab	CD44	Bivatuzumab can direct against CD44v6, blocking CD44-HA interaction	[247,248]
RO5429083	CD44	A monoclonal CD44 antibody, block the interaction between CD44 and HA, which have been entered phase 1 clinical trial conducted among patients with CD44-expressing malignant tumors	[249]
Verbascoside	CD44	Verbascoside suppressed growth of glioblastoma cells by inhibiting CD44 dimerization, as well as suppress tumor stem cell formation	[250]
7rh	DDR1	Inhibition of DDR1 by 7rh reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma	[251]
WRG-28	DDR2	By targeting DDR2, WRG-28 can efficiently prevent disrupt DDR2 receptor-collagen ligand interaction and DDR- mediated tumor progression in preclinical models	[252]
Imatinib, nilotinib and dasatinib	DDR1 and DDR2	These 3 compounds are potent inhibitors of both DDR1 and DDR2 by inhibiting collagen- induced discoidin domain receptor 1 and 2 activation	[253–255]
Fresolimumab	Collagen	An anti-TGF- β antibody, suppress TGF- β -regulated gene expression, decreases collagen synthesis, it is currently tested in a phase 1 clinical trial	[256,257]
Losartan	Collagen	Losartan inhibits collagen I production via TGF- β pathways and improves the distribution and efficacy of nanotherapeutics in tumors	[258]
Simtuzumab	LOXL2	Simtuzumab (GS-6624) is a selective inhibitor of LOXL2, which suppress LOXL2 enzymatic activity and inhibits collagen crosslinking, it is currently tested in a phase II clinical trial to test the efficacy and safety of GS-6624 combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma	[259,260]
(2-Chloropyridin-4-yl) methanamine hydrochloride	LOXL2	(2-Chloropyridin-4-yl) methanamine hydrochloride is a small molecule inhibitor of LOXL2, it suppresses transformation abilities by repressing LOX2 induced EMT in cervical cancer	[261]
CCT365623	LOX	CCT365623 is a pharmacological inhibitor of LOX, it disrupts TGF β 1/ HTRA1/ MATN2/EGFR signaling axis and reduces tumor progression.	[262]
Cilengitide	α v β 3 and α v β 5 integrin	Cilengitide is an inhibitor of α v β 3 and α v β 5 integrin, demonstrated modest antitumor activity among recurrent glioblastoma multiforme patients in a prior phase I study	[263]
Curcumin	α v β 3 integrin	Curcumin is a natural derivative of turmeric, it influences α v β 3 integrin expression and up-regulation of PDK4 in Erlotinib resistant SW480 colon cancer cells	[264]
Defactinib(VS-6063)	FAK	Defactinib is a FAK inhibitor which targets FAK catalytic activity, FAK is a key mediator of therapeutic resistance, it is a potential inhibitor to overcome adaptive resistance to chemotherapy, combinations with the other therapy drugs (such as Pembrolizumab; Paclitaxel and carboplatin; VS-6766) have been tested in the clinical trial phase I or II	[265–267]
IN10018	FAK	IN10018 is a highly selective oral inhibitor of FAK, it is currently tested in a phase Ib clinical trial to study of IN10018 in combination with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer	[268]
GSK2256098	FAK	GSK2256098 is an ATPcompetitive inhibitor that binds to the ATP-binding pocket of FAK, it is currently tested in a phase 1 clinical trial to study of GSK2256098 in patients with advanced solid tumors in the United Kingdom	[269,270]
BI853520	FAK	BI853520 is a highly selective ATP-competitive inhibitor of FAK, it is currently tested in a phase I clinical trial to study of BI853520 in patients with advanced or metastatic nonhematologic malignancies	[271]

Table 2

Targeting stromal cells and immune cells.

Inhibitor	Target cell	Target	Effectiveness	Reference
AMD3100	CAFs	CXCR4 specific inhibitor	Inhibit CAFs-induced EMT, migration and invasion	[94]
Siltuximab	CAFs	IL-6 blocking antibody	Inhibit tumor growth, showed anti-tumor activity in Phase I/II clinical study	[284,290,291]
Tocilizumab	CAFs	IL-6R blocking antibody	Inhibit CAFs-induced EMT, migration and invasion, repress tumor growth	[285]
Nab-paclitaxel	CAFs	Decrease IL-6 secretion	Inhibit CAFs-induced EMT and invasion	[288]
PHA-665752	CAFs	c-Met inhibitor	Inhibit CAFs-induced migration and invasion	[74]
SOM230 (pasireotide)	CAFs	Protein synthesis inhibitor	Inhibit CAFs-induced EMT, migration and invasion	[287]
BGB324	CAFs	AXL inhibitor	Inhibit CAFs-induced EMT and migration	[292]
SB431542-pirfenidone	CAFs	TGF- β 1 inhibitor	Inhibit CAFs-induced EMT and migration	[294]
ADP335	CAAs	Adiponectin analog	Inhibit tumor growth	[295,296]
PEG-LPrA2	CAAs	Leptin peptide receptor antagonist	Inhibit tumor growth	[297,298]
BMS 309403	CAAs	FABP4 inhibitor	Inhibit Adipocytes-mediated EMT, repress tumor metastasis	[106]
Niclosamide	CAAs	Potent STAT3 inhibitor	Inhibit Adipocytes-mediated EMT	[299]
D-CAN	CAAs	ASCs depletion	Inhibit obesity-associated EMT, improve chemotherapy outcome	[111,300]
α -TGF β / α -PD-1	T lymphocytes	PD-1 and TGF β blocking antibody	α -PD-1 boost T cell response, α -TGF β block α -PD-1-stimulated EMT, TGF β / α -PD-1 combination inhibit tumor growth and promote mice survival	[301]
SAR439459/ α -PD-L1	T lymphocytes	TGF β inhibitor /PD-1 blocking antibody	Promote anti-tumor immunity, induce tumor regression	[302]
M7824	T lymphocytes	PD-1 and TGF β blocking antibody	Inhibit TGF β -mediated EMT, block PD-L1, booster T cell response, inhibit tumor growth, metastasis, promote mice survival, show promising efficacy in clinical phase I	[303–307]
YM101	T lymphocytes	PD-L1 and TGF β blocking antibody	Enhance anti-tumor immune response, inhibit EMT, invasion and tumor growth	[308]
AZD6244/Anti-PD-L1/ Anti-IL-17	T lymphocytes	MEK inhibitor, IL-17 and PD-L1 blocking antibody	Overcome Th17-mediated therapy resistance, reduce tumor growth and lung metastasis	[309]
RDC018	TAMs	CCR2 antagonist	Inhibit TAM infiltration, repress M2 polarization, stimulate CD8 +T cell response	[310]
BLZ945	TAMs	CSF-1R inhibitor	Repress M2 polarization, induce established tumor regression	[311]
PLX3397	TAMs	CSF1R inhibitor	Reduce tumor burden, inhibit metastasis, prolong metastasis-free survival	[312]
RG7155	TAMs	CSF-1R mAb	Reduces TAMs, increase T cell infiltration	[313]
CP-870,893	TAMs	CD40 agonist mAb	Reprogram TAMs, FGK45 combined with gemcitabine therapy inhibit PDA tumor in mice, showed anti-tumor activity in Phase I study	[314]
BAY11-7082	TAMs	NF- κ B inhibitor	Reprogram TAMs, Inhibit TAMs-mediated EMT	[139]
IPI-549	TAMs	PI3K γ inhibitor	Reprogram TAMs, inhibit tumor metastasis	[315]
JWH-015	TAMs	Cannabinoid receptor-2 agonist	Inhibit TAMs-mediated EMT	[316]

Inhibitor	Target cell	Target	Effectiveness	Reference
Gemcitabine	MDSCs	Thymidylate synthetase inhibitor	Induce MDSCs apoptosis, combined with IFN- β to inhibit tumor growth	[317]
5-fluorouracil (5FU)	MDSCs	Thymidylate synthetase inhibitor	Induce MDSCs apoptosis, inhibit tumor growth	[318]
Sunitinib	MDSCs	Receptor tyrosine kinase inhibitor	Induce MDSCs apoptosis	[319]
Paclitaxel	MDSCs	Microtubule stabilization	Reduce MDSCs	[320]
Peptide-Fc	MDSCs	S100 family protein binding	Reduce MDSCs, restore CD8 ⁺ Teff activity, reduce tumor burden and prolong mice survival	[321]
PLX647, PLX5622	MDSCs	CSF-1R inhibitor	Block MDSCs recruitment, combine with anti-PD-L1 and anti CTLA-4 inhibit tumor growth and prolong mice survival	[322]
CCR5-Ig	MDSCs	CCR5 ligand neutralizer	Block MDSC and Tregs trafficking, inhibit tumor progression and prolong mice survival	[323]
SX682	MDSCs	CXCR2 inhibitor	Block PMN-MDSC recruitment, combined with anti-PD-1 inhibit tumor growth and prolong mice survival	[324]
Sildenafil	MDSCs	PDE5 inhibitor	Repress MDSC function, enhance T cell therapy efficacy	[325]
Celecoxib	MDSCs	COX-2 inhibitor	Deplete MDSC, impair MDSC function, combined with DC immunotherapy to improve mice survival	[326]
CDDO-Me	MDSCs	Reduce ROS	Neutralize MDSC activity, inhibit tumor growth	[327]
TBCA	MDSCs	CK2 inhibitor	Improve myeloid cell differentiation, inhibit tumor growth	[328]
ATRA	MDSCs	CK2 inhibitor	Improve dendritic cell differentiation	[329]

Table 3

Targeting hypoxia.

Inhibitor	Target	Mechanism	Effectiveness	Reference
chetomin	HIF-1 α , HIF-2 α	Inhibit p300 binding to HIF-1 α /2 α	Induce tumor necrosis	[347]
YC-1	HIF-1 α , HIF-2 α	Decrease HIF-1 α /2 α protein, inhibit p300 binding via FIH	Inhibit hypoxia-mediated migration, invasion and tumor metastasis	[349]
Bortezomib	HIF-1 α	Inhibit p300 binding via FIH	Induce tumor cell death	[348]
Echinomycin (NSC-13502)	HIF-1 α	Inhibit HIF-1 α /DNA interface	Inhibit hypoxia-mediated EMT, reduce metastasis in mice model, but show toxicity and limited efficacy in clinical phase II	[344-346]
PX-478	HIF-1 α	Inhibit HIF-1 α transcription, translation and ubiquitination	Inhibit tumor growth and metastasis	[350,351]
Acerflavine	HIF-1 α , HIF-2 α	Inhibit Dimerization with HIF-1 β	Inhibit tumor growth and metastasis	[342]
Digoxin	HIF-1 α , HIF-2 α	Inhibit HIF-1 α /2 α protein synthesis	Inhibit hypoxia-mediated EMT, migration and invasion. Reduce metastasis in mice model, but phase II clinical trial showed no effects	[338,339,356]
EZN-2968	HIF-1 α	Reduce HIF-1 α mRNA level	Inhibit tumor growth. Clinal trial was premature closed	[357,358]
Topotecan	HIF-1 α	Inhibit HIF-1 α translation	Inhibit tumor growth and angiogenesis, show effective anti-tumor activity in clinical phase I/II/III	[340,341,359]
2-methoxyestradiol (2ME2)	HIF-1 α , HIF-2 α	Inhibit HIF nuclear accumulation by disrupt tubulin	Inhibit angiogenesis	[343]
PT2399	HIF-2 α	blocks the heterodimerization of HIF-2 α with HIF-1 β	Inhibit tumor growth, induce tumor regression	[360,361]
PT2385	HIF-2 α	blocks the heterodimerization of HIF-2 α with HIF-1 β	Induce tumor regression	[362,363]
Belzutifan (MK-6482, PT2977)	HIF-2 α	blocks the heterodimerization of HIF-2 α with HIF-1 β	Induce tumor regression, safe and efficient in Phase I/II clinical trials	[364,365]